<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Biores Open Access</journal-id>
<journal-id journal-id-type="iso-abbrev">Biores Open Access</journal-id>
<journal-id journal-id-type="publisher-id">biores</journal-id>
<journal-title-group>
<journal-title>BioResearch Open Access</journal-title>
</journal-title-group>
<issn pub-type="ppub">2164-7844</issn>
<issn pub-type="epub">2164-7860</issn>
<publisher>
<publisher-name>Mary Ann Liebert, Inc.</publisher-name>
<publisher-loc>140 Huguenot Street, 3rd FloorNew Rochelle, NY 10801USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29291141</article-id>
<article-id pub-id-type="pmc">5747116</article-id>
<article-id pub-id-type="publisher-id">10.1089/biores.2017.0036</article-id>
<article-id pub-id-type="doi">10.1089/biores.2017.0036</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Comprehensive Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Epigenetic Treatment of Neurodegenerative Ophthalmic Disorders: An Eye Toward the Future</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Moos</surname>
<given-names>Walter H.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1,</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2,</sup>
</xref>
<xref ref-type="corresp" rid="corr1">
<sup>*</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Faller</surname>
<given-names>Douglas V.</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3,</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Glavas</surname>
<given-names>Ioannis P.</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Harpp</surname>
<given-names>David N.</given-names>
</name>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Irwin</surname>
<given-names>Michael H.</given-names>
</name>
<xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kanara</surname>
<given-names>Iphigenia</given-names>
</name>
<xref ref-type="aff" rid="aff8">
<sup>8</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pinkert</surname>
<given-names>Carl A.</given-names>
</name>
<xref ref-type="aff" rid="aff9">
<sup>9</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Powers</surname>
<given-names>Whitney R.</given-names>
</name>
<xref ref-type="aff" rid="aff10">
<sup>10,</sup>
</xref>
<xref ref-type="aff" rid="aff11">
<sup>11</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Steliou</surname>
<given-names>Kosta</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4,</sup>
</xref>
<xref ref-type="aff" rid="aff12">
<sup>12</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vavvas</surname>
<given-names>Demetrios G.</given-names>
</name>
<xref ref-type="aff" rid="aff13">
<sup>13,</sup>
</xref>
<xref ref-type="aff" rid="aff14">
<sup>14,</sup>
</xref>
<xref ref-type="corresp" rid="corr1">
<sup>*</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kodukula</surname>
<given-names>Krishna</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2,</sup>
</xref>
<xref ref-type="aff" rid="aff12">
<sup>12,</sup>
</xref>
<xref ref-type="aff" rid="aff15">
<sup>15,</sup>
</xref>
<xref ref-type="corresp" rid="corr1">
<sup>*</sup>
</xref>
</contrib>
<aff id="aff1"><label><sup>1</sup></label>Department of Pharmaceutical Chemistry, School of Pharmacy, <institution>University of California San Francisco</institution>, San Francisco, California.</aff>
<aff id="aff2"><label><sup>2</sup></label><institution>ShangPharma Innovation, Inc.</institution>, South San Francisco, California.</aff>
<aff id="aff3"><label><sup>3</sup></label>Department of Medicine, <institution>Boston University School of Medicine</institution>, Boston, Massachusetts.</aff>
<aff id="aff4"><label><sup>4</sup></label>Cancer Research Center, <institution>Boston University School of Medicine</institution>, Boston, Massachusetts.</aff>
<aff id="aff5"><label><sup>5</sup></label>Department of Ophthalmology, <institution>New York University School of Medicine</institution>, New York, New York.</aff>
<aff id="aff6"><label><sup>6</sup></label>Department of Chemistry, <institution>McGill University</institution>, Montreal, QC, <country>Canada</country>.</aff>
<aff id="aff7"><label><sup>7</sup></label>Department of Pathobiology, College of Veterinary Medicine, <institution>Auburn University</institution>, Auburn, Alabama.</aff>
<aff id="aff8"><label><sup>8</sup></label><institution>Embassy of Greece in Moscow</institution>, Moscow, <country>Russia</country>.</aff>
<aff id="aff9"><label><sup>9</sup></label>Department of Biological Sciences, College of Arts and Sciences, <institution>The University of Alabama</institution>, Tuscaloosa, Alabama.</aff>
<aff id="aff10"><label><sup>10</sup></label>Department of Health Sciences, <institution>Boston University</institution>, Boston, Massachusetts.</aff>
<aff id="aff11"><label><sup>11</sup></label>Department of Anatomy, <institution>Boston University School of Medicine</institution>, Boston, Massachusetts.</aff>
<aff id="aff12"><label><sup>12</sup></label><institution>PhenoMatriX, Inc.</institution>, Natick, Massachusetts.</aff>
<aff id="aff13"><label><sup>13</sup></label>Retina Service, Angiogenesis Laboratory, <institution>Massachusetts Eye and Ear Infirmary</institution>, Boston, Massachusetts.</aff>
<aff id="aff14"><label><sup>14</sup></label>Department of Ophthalmology, <institution>Harvard Medical School</institution>, Boston, Massachusetts.</aff>
<aff id="aff15"><label><sup>15</sup></label><institution>Bridgewater College</institution>, Bridgewater, Virginia.</aff>
</contrib-group>
<author-notes>
<corresp id="corr1"><label><sup>*</sup></label>Address correspondence to: Walter H. Moos, PhD, Department of Pharmaceutical Chemistry, School of Pharmacy, University of California San Francisco, UCSF Box 2280, 600 16th Street, Genentech Hall S512D, San Francisco, CA 94143, E-mail: <email xlink:href="mailto:walter.moos@ucsf.edu">walter.moos@ucsf.edu</email><italic>or</italic> Demetrios G. Vavvas, MD, PhD, Retina Service, Angiogenesis Laboratory, Massachusetts Eye and Ear Infirmary, 243 Charles Street, Boston, MA 02114, E-mail: <email xlink:href="mailto:vavvas@meei.harvard.edu">vavvas@meei.harvard.edu</email><italic>or</italic> Krishna Kodukula, PhD, ShangPharma Innovation, Inc., 280 Utah Avenue, South San Francisco, CA 94080, E-mail: <email xlink:href="mailto:kkodukula@gmail.com">kkodukula@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>01</day>
<month>12</month>
<year>2017</year>
<!--string-date: December 2017-->
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>12</month>
<year>2017</year>
<!--string-date: December 2017-->
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
<volume>6</volume>
<issue>1</issue>
<fpage>169</fpage>
<lpage>181</lpage>
<permissions>
<copyright-statement>© Walter H. Moos <italic>et al</italic>. 2017; Published by Mary Ann Liebert, Inc.</copyright-statement>
<copyright-year>2017</copyright-year>
<license license-type="open-access">
<license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="biores.2017.0036.pdf" xlink:type="simple"></self-uri>
<abstract>
<title>Abstract</title>
<p>Eye disease is one of the primary medical conditions that requires attention and therapeutic intervention in ageing populations worldwide. Further, the global burden of diabetes and obesity, along with heart disease, all lead to secondary manifestations of ophthalmic distress. Therefore, there is increased interest in developing innovative new approaches that target various mechanisms and sequelae driving conditions that result in adverse vision. The research challenge is even greater given that the terrain of eye diseases is difficult to landscape into a single therapeutic theme. This report addresses the burden of eye disease due to mitochondrial dysfunction, including antioxidant, autophagic, epigenetic, mitophagic, and other cellular processes that modulate the biomedical end result. In this light, we single out lipoic acid as a potent known natural activator of these pathways, along with alternative and potentially more effective conjugates, which together harness the necessary potency, specificity, and biodistribution parameters required for improved therapeutic outcomes.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title><bold>Keywords:</bold> </title>
<kwd>antioxidant</kwd>
<kwd>carnitine</kwd>
<kwd>lipoic acid</kwd>
<kwd>macular degeneration</kwd>
<kwd>mitochondria</kwd>
<kwd>retina</kwd>
</kwd-group>
<counts>
<fig-count count="2"></fig-count>
<table-count count="4"></table-count>
<ref-count count="241"></ref-count>
<page-count count="13"></page-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s001" sec-type="intro">
<title>Introduction</title>
<p>Given the importance of vision and the number of age-related causes of vision loss (<xref ref-type="table" rid="T1">Table 1</xref>), including cataracts and macular degeneration,<sup><xref ref-type="bibr" rid="B1">1–3</xref></sup> losing the ability to see is one of the greatest fears among the elderly, to some even more than death itself.<sup><xref ref-type="bibr" rid="B4">4</xref></sup> The Ancient Greeks regarded vision to be the foremost means by which learning takes place. As early as the latter half of the 6th century Before the Common Era, the philosopher Alcmaeon of Croton<sup><xref ref-type="bibr" rid="B5">5</xref></sup> believed that the eyes are connected directly to the brain.<sup><xref ref-type="bibr" rid="B6">6</xref></sup> Two centuries later, by dissecting the human eye during autopsies on cadavers carried out in Alexandria, the Greek physician Herophilus of Chalcedon<sup><xref ref-type="bibr" rid="B5">5</xref></sup> identified the optic nerves, tracing them directly to the brain.<sup><xref ref-type="bibr" rid="B7">7</xref></sup> Today, the subject of the eye and the brain has in many places become required reading for students of life sciences. For example, Gregory's book,<sup><xref ref-type="bibr" rid="B8">8</xref></sup> “Eye and Brain,” has been a classic since its first edition in 1966.</p>
<table-wrap id="T1" orientation="portrait" position="float">
<label>Table 1.</label>
<caption>
<p>
<bold>Major Causes of Vision Loss Worldwide</bold>
</p>
</caption>
<!--OASIS TABLE HERE-->
<table frame="hsides" rules="groups">
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Causes</th>
<th align="center">Characteristics</th>
<th align="center">Ranking as a cause of blindness in 2010</th>
<th align="center">Ranking as a cause of MSVI in 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Cataracts</td>
<td align="left">Age-related, progressive</td>
<td align="center">1</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">Diabetic retinopathy</td>
<td align="left">Including sequelae</td>
<td align="center">4</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">Glaucoma</td>
<td align="left">All types</td>
<td align="center">2</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">Macular degeneration</td>
<td align="left">Age-related, myopic, macular hole, and other forms</td>
<td align="center">3</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">Refractive errors (uncorrected)</td>
<td align="left">Includes aphakia</td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">Trachoma</td>
<td align="left"> </td>
<td align="center">5</td>
<td align="center">6</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tf1">
<p>Selected sources: Bourne et al.,<sup><xref ref-type="bibr" rid="B1">1</xref></sup> Tham et al.,<sup><xref ref-type="bibr" rid="B2">2</xref></sup> Wong et al.,<sup><xref ref-type="bibr" rid="B3">3</xref></sup> Aires et al.<sup><xref ref-type="bibr" rid="B9">9</xref></sup></p>
</fn>
<fn id="tf2">
<p>MSVI, moderate to severe vision impairment.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The human eye (<xref ref-type="fig" rid="f1">Fig. 1</xref>) is a conveniently accessible, anatomically complex, highly specialized sensory organ with pharmacological properties that are largely organ-specific.<sup><xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref></sup> These properties present unique opportunities to study effects of inflammation and infectious diseases in the eye, with relevance to the brain and central and autonomic nervous systems.<sup><xref ref-type="bibr" rid="B10">10</xref></sup> The retina and optic nerve extend from the brain tissue.<sup><xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref></sup> Similar to the brain, sheltered by the blood–brain barrier as an immune-privileged tissue, the eye is also an immunologically privileged site protected by the blood-retinal barrier.<sup><xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B13">13–15</xref></sup> The retina is one of the highest metabolic oxygen-consuming tissues of the human body, exceeding even that of the brain,<sup><xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref></sup> and its photoreceptors have the greatest density of mitochondria of all central nervous system (CNS) neurons.<sup><xref ref-type="bibr" rid="B17">17–19</xref></sup> Mitochondria are intracellular organelles that carry multiple copies of a circular, maternally inherited, double-stranded DNA (mtDNA) comprised of ∼16,500 base pairs in mammals. A principal role of mitochondria is to supply adenosine triphosphate (ATP), the bioenergy needed for cellular maintenance and other essential biochemical processes.<sup><xref ref-type="bibr" rid="B20">20</xref></sup> Importantly, when there is a buildup of damaged and/or dysfunctional mitochondria in the optic nerve, the nerve's diminished capacity to produce enough ATP to supply its energy demands can result in severe visual impairment and lead to blindness.<sup><xref ref-type="bibr" rid="B21">21–24</xref></sup></p>
<fig fig-type="figure" id="f1" orientation="portrait" position="float">
<label>
<bold>FIG. 1.</bold>
</label>
<caption>
<p>Basic structure of the human eye. (Adapted from: Artwork by Holly Fischer [CC BY 3.0 (<uri xlink:href="http://creativecommons.org/licenses/by/3.0" xlink:type="simple">http://creativecommons.org/licenses/by/3.0</uri>)], via Wikimedia Commons. Original File URL: <uri xlink:href="http://upload.wikimedia.org/wikipedia/commons/d/d0/Three_Main_Layers_of_the_Eye.png" xlink:type="simple">https://upload.wikimedia.org/wikipedia/commons/d/d0/Three_Main_Layers_of_the_Eye.png</uri>).</p>
</caption>
<graphic xlink:href="fig-1"></graphic>
</fig>
<p>Mitochondrial dysfunction is a prominent feature in the disease-progression mechanisms and pathways of a growing list of clinical disorders.<sup><xref ref-type="bibr" rid="B25">25–33</xref></sup> Included among these are vision impairments such as cataracts,<sup><xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B34">34</xref></sup> the most common cause of (preventable) blindness in the world,<sup><xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B36">36</xref></sup> macular degeneration,<sup><xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B37">37–42</xref></sup> diabetic retinopathy,<sup><xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B43">43–45</xref></sup> and optic nerve diseases<sup><xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B46">46</xref>,<xref ref-type="bibr" rid="B47">47</xref></sup> such as glaucoma.<sup><xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B48">48</xref></sup> Glaucoma, an umbrella term for eye conditions that are caused by glaucomatous optic neuropathy, characterized by a progressive retinal ganglion cell loss and visual field damage,<sup><xref ref-type="bibr" rid="B47">47</xref>,<xref ref-type="bibr" rid="B49">49</xref>,<xref ref-type="bibr" rid="B50">50</xref></sup> is the second leading cause of blindness worldwide.<sup><xref ref-type="bibr" rid="B9">9</xref></sup> However, the ultimate form of mitochondrial dysfunction is expressed in the primary mitochondrial disorders<sup><xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B51">51</xref>,<xref ref-type="bibr" rid="B52">52</xref></sup> and, with the brain and eye being insatiable consumers of ATP, it is not surprising that neuronal and/or ocular health are inevitable frontline casualties in these diseases.<sup><xref ref-type="bibr" rid="B53">53–55</xref></sup></p>
<p>In fact, (neuro-)ophthalmologic assessment<sup><xref ref-type="bibr" rid="B56">56</xref></sup> is very much in order when mitochondrial disease is suspected (<xref ref-type="table" rid="T2">Table 2</xref>),<sup><xref ref-type="bibr" rid="B57">57–59</xref></sup> even though significant clinical and genetic heterogeneity is evident in mtDNA mutation-driven disorders.<sup><xref ref-type="bibr" rid="B60">60</xref></sup> In one study, 26 of 74 adult and pediatric patients with mitochondrial disease exhibited ophthalmologic abnormalities,<sup><xref ref-type="bibr" rid="B61">61</xref></sup> and in another, 46 of 57 children and young adults with genetically verified mitochondrial disease had ophthalmologic findings.<sup><xref ref-type="bibr" rid="B62">62</xref></sup> Signs of potential ocular involvement in mitochondrial disease may include hyperpigmentation of the retina, nystagmus, ptosis, ophthalmoplegia, optic atrophy, strabismus, and visual field defects. More extensive examination of the eye is required when the optic nerve itself is involved. Examples of the latter include autosomal dominant optic atrophy-related disorders and Leber's hereditary optic neuropathy.<sup><xref ref-type="bibr" rid="B63">63</xref></sup></p>
<table-wrap id="T2" orientation="portrait" position="float">
<label>Table 2.</label>
<caption>
<p>
<bold>Selected Mitochondrial Diseases and Associated Clinical or Neurological Ophthalmologic Features</bold>
</p>
</caption>
<!--OASIS TABLE HERE-->
<table frame="hsides" rules="groups">
<colgroup>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Representative mitochondrial diseases and associated clinical/neurological features</th>
<th align="center">Alternative names and/or causes</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Chronic progressive external ophthalmoplegia</td>
<td align="left">CPEO</td>
</tr>
<tr>
<td align="left">Encephalopathy with enteropathy, neuropathy, and progressive external ophthalmoplegia</td>
<td align="left">MNGIE</td>
</tr>
<tr>
<td align="left">Encephalopathy with cardiomyopathy, nephrotic syndrome, deafness, optic atrophy, and ataxia</td>
<td align="left">Coenzyme Q10 deficiency</td>
</tr>
<tr>
<td align="left">Leigh's disease</td>
<td align="left">Subacute necrotizing encephalomyelopathy</td>
</tr>
<tr>
<td align="left">Leber's hereditary optic neuropathy</td>
<td align="left">LHON</td>
</tr>
<tr>
<td align="left">Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes</td>
<td align="left">MELAS</td>
</tr>
<tr>
<td align="left">Mitochondrial DNA deletions or depletion</td>
<td align="left">mtDNA deletions or depletion</td>
</tr>
<tr>
<td align="left">Myoclonus epilepsy with ragged-red fibers</td>
<td align="left">MERRF</td>
</tr>
<tr>
<td align="left">Neuropathy, ataxia, and retinitis pigmentosa</td>
<td align="left">NARP; secondary to mtDNA mutation in MT-ATP6</td>
</tr>
<tr>
<td align="left">Nuclear DNA point mutations</td>
<td align="left">nDNA point mutations</td>
</tr>
<tr>
<td align="left">Pearson's/Kearns-Sayre syndrome</td>
<td align="left">Pearson's/KSS</td>
</tr>
<tr>
<td align="left">Progressive external ophthalmoparesis</td>
<td align="left">PEO</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tf3">
<p>Sources: Zhu et al.,<sup><xref ref-type="bibr" rid="B61">61</xref></sup> Grönlund et al.,<sup><xref ref-type="bibr" rid="B62">62</xref></sup> McFarland et al.,<sup><xref ref-type="bibr" rid="B63">63</xref></sup> Yu-Wai-Man and Newman.<sup><xref ref-type="bibr" rid="B64">64</xref></sup></p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Although mitochondria in their production of ATP serve as the powerhouses of the cell,<sup><xref ref-type="bibr" rid="B20">20</xref></sup> they also function as strategic platforms for intracellular signaling, as modulators of stem cell activity and cell death pathways, and as regulators of innate and adaptive immune responses to viral infections and other biological attacks.<sup><xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B65">65–71</xref></sup> Indeed, a growing list of studies exposing the pivotal roles mitochondria play in immune-related pathways<sup><xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B68">68</xref>,<xref ref-type="bibr" rid="B70">70–77</xref></sup> is fueling the characterization of mitochondria as the powerhouses of immunity.<sup><xref ref-type="bibr" rid="B78">78</xref></sup> Thus, given these essential processes that mitochondria undertake in mitigating cell protection, survival, and function, they are attractive targets of opportunity for diagnostic, prognostic, and therapeutic indications, particularly in diseases of tissues with high energy needs.<sup><xref ref-type="bibr" rid="B79">79</xref></sup> Breakthroughs in diagnosing and treating neurological disorders are in great need<sup><xref ref-type="bibr" rid="B29">29–32</xref>,<xref ref-type="bibr" rid="B80">80–82</xref></sup> and the eye, being an accessible part of the brain, offers a clear window for us to begin to explore.</p>
</sec>
<sec id="s002">
<title>Ocular Manifestations of Neurological Conditions and Disorders</title>
<p>For more than two millennia, physicians have looked to the eye as a sentinel indicator of disease.<sup><xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B83">83</xref></sup> Abnormal avoidance of eye contact is an early risk-marker associated with autism.<sup><xref ref-type="bibr" rid="B84">84–86</xref></sup> Several neurodegenerative conditions—Alzheimer's disease (AD), inherited primary mitochondrial diseases, Parkinson's disease, and multiple sclerosis among others—have manifestations in the eye. Indeed, ocular symptoms often precede conventional diagnosis of these conditions.<sup><xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B55">55</xref>,<xref ref-type="bibr" rid="B56">56</xref>,<xref ref-type="bibr" rid="B87">87–97</xref></sup> In addition to when the eye itself is the target of infection, ocular symptoms are also common to viral diseases that affect the brain and CNS.<sup><xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B98">98–102</xref></sup> Healthy mitochondrial function is necessary in upholding a competent innate immunity, the body's frontline response against viral infections.<sup><xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B76">76</xref>,<xref ref-type="bibr" rid="B78">78</xref></sup> Although these varied types of neurological and related conditions and disorders can have disparate root causes, they share in common mitochondrial dysfunction in their disease progression pathways.<sup><xref ref-type="bibr" rid="B26">26–32</xref>,<xref ref-type="bibr" rid="B65">65</xref></sup> Consequently, the eye, not infrequently the first neuronal tissue affected by mitochondrial failure, offers itself as a model for energetic impairment in the CNS with direct implications for degenerative brain diseases<sup><xref ref-type="bibr" rid="B53">53</xref></sup> (<xref ref-type="table" rid="T3">Table 3</xref>).</p>
<table-wrap id="T3" orientation="portrait" position="float">
<label>Table 3.</label>
<caption>
<p>
<bold>Association of Vision Loss with Other Diseases</bold>
</p>
</caption>
<!--OASIS TABLE HERE-->
<table frame="hsides" rules="groups">
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Eye disease/indication</th>
<th align="center">Cause/associated condition</th>
<th align="center">Disease progression</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Diabetic retinopathy<sup><xref ref-type="bibr" rid="B45">45</xref></sup></td>
<td align="left">Diabetes</td>
<td align="left">Progressive degeneration leading to blindness</td>
</tr>
<tr>
<td align="left">Macular degeneration<sup><xref ref-type="bibr" rid="B103">103</xref></sup></td>
<td align="left">Aging, complement dysregulation, oxidation, mitochondrial dysfunction</td>
<td align="left">Progressive degeneration leading to legal blindness</td>
</tr>
<tr>
<td align="left">Microvascular abnormalities<sup><xref ref-type="bibr" rid="B104">104</xref>,<xref ref-type="bibr" rid="B105">105</xref></sup></td>
<td align="left">AD, diabetes, cardiovascular disease</td>
<td align="left"> </td>
</tr>
<tr>
<td align="left">Optic nerve cupping, optic neuropathy<sup><xref ref-type="bibr" rid="B104">104</xref></sup></td>
<td align="left">Glaucoma, ischemic optic neuropathies. Compressive optic neuropathies</td>
<td align="left"> </td>
</tr>
<tr>
<td align="left">Pupillary abnormalities<sup><xref ref-type="bibr" rid="B104">104</xref></sup></td>
<td align="left">AD, diabetes, optic nerve and CNS abnormalities</td>
<td align="left"> </td>
</tr>
<tr>
<td align="left">Retinal neurodegeneration (thinning of RNFL)<sup><xref ref-type="bibr" rid="B104">104</xref></sup></td>
<td align="left">AD, PD</td>
<td align="left"> </td>
</tr>
<tr>
<td align="left">RP<sup><xref ref-type="bibr" rid="B64">64</xref>,<xref ref-type="bibr" rid="B106">106</xref></sup></td>
<td align="left">Several hundred genes isolated to day</td>
<td align="left">Progressive blindness</td>
</tr>
<tr>
<td align="left">Usher syndrome<sup><xref ref-type="bibr" rid="B107">107</xref></sup></td>
<td align="left">Deafness coupled with RP</td>
<td align="left">Progressive degeneration and deterioration</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tf4">
<p>AD, Alzheimer's disease; PD, Parkinson's disease; RNFL, retinal nerve fiber layer; RP, retinitis pigmentosa.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s003">
<title>Targeting Mitochondrial Dysfunction in Ocular Diseases</title>
<p>Many of the familiar features of aging seen in aged animals (including humans) correlate with epigenetic alterations that regulate transcription.<sup><xref ref-type="bibr" rid="B108">108–110</xref></sup> Nutritional disequilibrium, epigenetic changes in gene expression, increased genomic instability, an erosion of telomeres, increased cellular senescence, and deregulated nutrient sensing are some of the age-related functional characteristics acting on or with each other that impact other hallmarks such as mitochondrial function and/or dysfunction and the degradation of an appropriate immune response.<sup><xref ref-type="bibr" rid="B66">66</xref>,<xref ref-type="bibr" rid="B78">78</xref>,<xref ref-type="bibr" rid="B111">111–115</xref></sup></p>
<p>Because mitochondria cannot be produced <italic>de novo</italic>,<sup><xref ref-type="bibr" rid="B116">116</xref></sup> cells rely on the preservation of their healthy mitochondria from which mitochondrial biogenesis (the growth and division of pre-existing mitochondria) can occur. Mitophagy, a sub-form of autophagy,<sup><xref ref-type="bibr" rid="B70">70</xref>,<xref ref-type="bibr" rid="B72">72</xref>,<xref ref-type="bibr" rid="B117">117–120</xref></sup> clears away damaged and/or dysfunctional mitochondria.<sup><xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B71">71</xref>,<xref ref-type="bibr" rid="B75">75</xref>,<xref ref-type="bibr" rid="B111">111</xref>,<xref ref-type="bibr" rid="B120">120–127</xref></sup> Not surprisingly, given the irreplaceable nature of the mitochondrion and the indispensable roles mitochondria play in maintaining neuro-(ocular) health, mitoprotection has become an important target of pharmacological intervention—spawning an emerging pharmaceutical interest in developing “mitoprotectors,”<sup><xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B128">128–132</xref></sup> and therapeutics for activating antioxidant and/or select mitophagic pathways.<sup><xref ref-type="bibr" rid="B72">72</xref>,<xref ref-type="bibr" rid="B117">117</xref>,<xref ref-type="bibr" rid="B118">118</xref>,<xref ref-type="bibr" rid="B122">122</xref>,<xref ref-type="bibr" rid="B125">125</xref>,<xref ref-type="bibr" rid="B126">126</xref>,<xref ref-type="bibr" rid="B133">133–137</xref></sup> This includes dysregulated situations where these pathways and their modulators may be potentially maladaptive,<sup><xref ref-type="bibr" rid="B138">138–141</xref></sup> for example, wherein constraining the induction of autophagy or mitophagy is desirable.<sup><xref ref-type="bibr" rid="B142">142</xref></sup> However, when autophagy was inhibited in retinal pigment epithelial (RPE) cells subjected to rotenone-induced mitotic catastrophe (MC) <italic>in vivo</italic> (mice), it caused necrotic cell death—suggesting that cell-controlled autophagy and mitophagy act to prevent the RPE-MC cells from collectively plunging into cell death indiscriminately, and thus help minimize the extent of untoward RPE cell loss.<sup><xref ref-type="bibr" rid="B143">143</xref></sup></p>
</sec>
<sec id="s004">
<title>α-Lipoic Acid and L-Carnitine</title>
<p>(<italic>R</italic>)-5-(1,2-dithiolan-3-yl)pentanoic acid, commonly known as α-lipoic acid (ALA, <xref ref-type="fig" rid="f2">Fig. 2</xref>) and its reduced form (<italic>R</italic>)-6,8-bis(sulfanyl)octanoic acid, commonly referred to as dihydrolipoic acid (DHLA, <xref ref-type="fig" rid="f2">Fig. 2</xref>) are enzymatically synthesized in mitochondria from octanoic acid.<sup><xref ref-type="bibr" rid="B144">144</xref></sup> ALA and DHLA are naturally occurring cofactors for vital metabolic multi-enzyme complexes, including pyruvate dehydrogenase and glycine decarboxylase.<sup><xref ref-type="bibr" rid="B144">144–146</xref></sup> They possess powerful antioxidative effects<sup><xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B145">145</xref>,<xref ref-type="bibr" rid="B147">147</xref>,<xref ref-type="bibr" rid="B148">148</xref></sup> and anti-inflammatory activity,<sup><xref ref-type="bibr" rid="B149">149</xref></sup> instigate signal transduction modulatory pathways,<sup><xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B150">150</xref></sup> and are well known to stimulate the expression of nerve growth factor<sup><xref ref-type="bibr" rid="B148">148</xref>,<xref ref-type="bibr" rid="B151">151</xref>,<xref ref-type="bibr" rid="B152">152</xref></sup> and enhance conduction velocity of motor nerves.<sup><xref ref-type="bibr" rid="B148">148</xref>,<xref ref-type="bibr" rid="B153">153</xref></sup></p>
<fig fig-type="figure" id="f2" orientation="portrait" position="float">
<label>
<bold>FIG. 2.</bold>
</label>
<caption>
<p>ALA-conjugates: PMX500FI<sup><xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B154">154</xref>,<xref ref-type="bibr" rid="B155">155</xref></sup>; EV06<sup>156</sup>; Lipoamide-ibuprofen conjugates (<italic>n</italic> = 2; 4; 6)<sup><xref ref-type="bibr" rid="B157">157</xref>,<xref ref-type="bibr" rid="B158">158</xref></sup>; Lipoamide-rivastigmine conjugate, Lipocrine<sup><xref ref-type="bibr" rid="B159">159</xref></sup>; MiotL, revMitoLipAc<sup><xref ref-type="bibr" rid="B160">160</xref></sup>; Scopoletin lipoate.<sup><xref ref-type="bibr" rid="B161">161</xref></sup> ALA, α-lipoic acid.</p>
</caption>
<graphic xlink:href="fig-2"></graphic>
</fig>
<p>Additionally, ALA has significant histone deacetylase (HDAC) inhibitory activity.<sup><xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B145">145</xref></sup> It is a potent activator of the nuclear factor erythroid 2-related factor 2 (Nrf2)/antioxidant response element (ARE) signaling pathway,<sup><xref ref-type="bibr" rid="B28">28–32</xref>,<xref ref-type="bibr" rid="B162">162</xref>,<xref ref-type="bibr" rid="B163">163</xref></sup> which plays a central role in cellular defense against oxidative stress and the subsequent upregulation of ARE-dependent cytoprotective genes, including the heme oxygenase-1, catalase, and superoxide dismutase genes, without exhibiting cytotoxicity.<sup><xref ref-type="bibr" rid="B164">164</xref>,<xref ref-type="bibr" rid="B165">165</xref></sup> Nrf2 is essential for supporting and maintaining normal mitochondrial function and structural integrity, particularly under conditions of cellular/neuronal stress inherent in neurodegenerative disorders.<sup><xref ref-type="bibr" rid="B29">29</xref></sup> Oxidative stress is one of the main factors contributing to the pathogenesis of age-related macular degeneration (AMD),<sup><xref ref-type="bibr" rid="B39">39</xref>,<xref ref-type="bibr" rid="B40">40</xref>,<xref ref-type="bibr" rid="B166">166–169</xref></sup> the most common cause of blindness in the elderly<sup><xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B167">167</xref>,<xref ref-type="bibr" rid="B170">170</xref>,<xref ref-type="bibr" rid="B171">171</xref></sup> and the third-leading cause of blindness worldwide<sup><xref ref-type="bibr" rid="B3">3</xref></sup> (<xref ref-type="table" rid="T4">Table 4</xref>).</p>
<table-wrap id="T4" orientation="landscape" position="float">
<label>Table 4.</label>
<caption>
<p>
<bold>Characteristics of Age-Related Macular Degeneration</bold>
</p>
</caption>
<!--OASIS TABLE HERE-->
<table frame="hsides" rules="groups">
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Forms or stages of AMD</th>
<th align="center">Degree of vision loss</th>
<th align="center">Prevalence</th>
<th align="center">Rate of progression</th>
<th align="center">Atrophy</th>
<th align="center">Neo-vascularization</th>
<th align="center">Other</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Early</td>
<td align="left">None</td>
<td align="left"> </td>
<td align="left"> </td>
<td align="left"> </td>
<td align="left"> </td>
<td align="left"> </td>
</tr>
<tr>
<td align="left">Intermediate</td>
<td align="left">Little or no vision loss; other symptoms may present such as decreased dark adaptation, decreased contrast sensitivity and metamorphopsia.</td>
<td align="left"> </td>
<td align="left"> </td>
<td align="left"> </td>
<td align="left"> </td>
<td align="left">Possible retinal pigment abnormalities (hypo or hyper)</td>
</tr>
<tr>
<td align="left">Late or advanced</td>
<td align="left">Loss of central vision</td>
<td align="left"> </td>
<td align="left"> </td>
<td align="left">Yes (atrophy and/or neo-vascularization)</td>
<td align="left">Yes (atrophy and/or neo-vascularization)</td>
<td align="left"> </td>
</tr>
<tr>
<td align="left">Dry</td>
<td align="left">Minimal symptoms in early stages</td>
<td align="center">80–90% of all AMD</td>
<td align="left">Gradual/insidious over months/years; may progress to wet AMD</td>
<td align="left">Possible geographic atrophy in advanced disease</td>
<td align="left">No; nonexudative</td>
<td align="left">Also known as nonexudative or non-neo-vascular AMD</td>
</tr>
<tr>
<td align="left">Wet</td>
<td align="left">Vision loss driven by damage to photoreceptors from bleeds, leaks, scars (resulting from abnormal blood vessels)</td>
<td align="left">10–15% of all AMD (but 80% of severe visual loss or legal blindness)</td>
<td align="left">Can be sudden/profound over days/weeks if untreated; often follows dry AMD</td>
<td align="left"> </td>
<td align="left">Yes; exudative</td>
<td align="left">Also known as neo-vascular AMD</td>
</tr>
<tr>
<td align="left">Geographic atrophy</td>
<td align="left">Progressive, irreversible loss of retinal cells causes losses in visual function</td>
<td align="left"> </td>
<td align="left"> </td>
<td align="left">Also called atrophic AMD</td>
<td align="left">Yes; abnormal growth of blood vessels</td>
<td align="left"> </td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tf5">
<p>Selected sources: Fine et al.,<sup><xref ref-type="bibr" rid="B172">172</xref></sup> de Jong,<sup><xref ref-type="bibr" rid="B173">173</xref></sup> Jager et al.<sup><xref ref-type="bibr" rid="B174">174</xref></sup></p>
</fn>
<fn id="tf6">
<p>AMD, age-related macular degeneration.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Nrf2-mediated activity has been shown to decrease in aged rodents compared to younger pups, and in humans, in macrophages from older smokers in comparison with older nonsmokers, and in the affected brain regions of AD patients.<sup><xref ref-type="bibr" rid="B166">166</xref></sup></p>
<p>Although ALA reaps much attention in clinical therapy against a host of diseases susceptible to reactive oxygen species, including radiation exposure scenarios and heavy metal toxicity,<sup><xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B175">175</xref></sup> its poor pharmacokinetic (PK) properties <sup><xref ref-type="bibr" rid="B43">43</xref>,<xref ref-type="bibr" rid="B176">176–179</xref></sup> are a barrier to achieving sustainable therapeutic concentrations <italic>in vivo</italic>.<sup><xref ref-type="bibr" rid="B163">163</xref>,<xref ref-type="bibr" rid="B177">177</xref>,<xref ref-type="bibr" rid="B180">180</xref>,<xref ref-type="bibr" rid="B181">181</xref></sup> This PK deficit limits the range of ALA's potential clinical indications. Nonetheless, ALA is an effective treatment option for diabetic neuropathy<sup><xref ref-type="bibr" rid="B43">43</xref>,<xref ref-type="bibr" rid="B182">182</xref></sup> and possibly helpful in diabetic retinopathy,<sup><xref ref-type="bibr" rid="B183">183</xref></sup> as outlined below.</p>
<p>In a clinical study evaluating oxidative stress, preretinopathic diabetic subjects who received oral treatment with ALA in combination with other antioxidants showed a significant benefit in retinal elements—presumably due to a protective antioxidant effect on retinal cells (as determined by electroretinogram analysis).<sup><xref ref-type="bibr" rid="B184">184</xref></sup> A protective antioxidant effect was also noted in a separate randomly assigned clinical trial involving 100 patients with dry AMD (50 patients given an oral administration of 0.2 g of ALA capsules daily for 3 months, and a control group of 50 patients receiving an oral administration of 1 g of vitamin C daily). Using the Chinese-Version Low Vision Quality of Life Questionnaire to assess vision-related quality of life, the ALA-treated group scored higher vs. the control group.<sup><xref ref-type="bibr" rid="B185">185</xref></sup> In a study using a rat model of optic nerve crush injury, ALA administered intravenously (63 mg/kg) 1 day before or 1 day after the ONC injury was shown to have neuroprotective effects on retinal ganglion cells and a stronger prophylactic effect in the retina of the ONC-rats receiving ALA the day before the ONC injury.<sup><xref ref-type="bibr" rid="B186">186</xref></sup> In a preliminary study with a higher species animal model (diabetic dogs) given ALA (2 mg/kg) orally, with ALA possibly acting as an antioxidant and/or as an aldose reductase inhibitor, the onset of glucose-sorbitol-induced cataracts was delayed, suggesting that the use of ALA should be studied for treating aldose-reductase-associated diabetic retinopathy in humans.<sup><xref ref-type="bibr" rid="B187">187</xref></sup></p>
<p>However, to more fully take advantage of ALA's clinical potential as a drug candidate (particularly in ocular indications), its PK drawbacks must be resolved. With this in mind, mitochondria-targeting ALA-conjugated esters were conceived and synthesized. Chemical structures representing some of the conjugates that have been shown to have improved bioavailability and activity <italic>in vivo</italic> are shown in <xref ref-type="fig" rid="f2">Figure 2</xref>.<sup><xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B154">154–161</xref>,<xref ref-type="bibr" rid="B188">188–190</xref></sup></p>
<p>EV06 and PMX500FI (<xref ref-type="fig" rid="f2">Fig. 2</xref>) are covalently linked esters of natural substrates (EV06: ALA and choline<sup><xref ref-type="bibr" rid="B156">156</xref></sup>; PMX500FI: ALA and L-carnitine<sup><xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B154">154</xref>,<xref ref-type="bibr" rid="B155">155</xref></sup>) that localize to and are operated on in mitochondria. A detailed and elegant study highlighting the anticancer properties of ALA (acting as a modulator of signal transduction and gene expression) inhibiting HDAC activity in human tumor cells was reported by van de Mark et al.<sup><xref ref-type="bibr" rid="B145">145</xref></sup> In this study, choline was used as the vehicle (control), as it apparently has no noteworthy activity of its own in the assays used. However, choline is an essential nutrient and methyl donor required for epigenetic regulation,<sup><xref ref-type="bibr" rid="B191">191</xref></sup> and choline acetyltransferase (an enzyme that catalyzes the biosynthesis of the neurotransmitter, acetylcholine) is well-represented in ocular tissues of the human eye<sup><xref ref-type="bibr" rid="B192">192</xref></sup> and in cholinergic cells of the brain and CNS.<sup><xref ref-type="bibr" rid="B193">193</xref></sup></p>
<p>L-Carnitine [L-(3<italic>R</italic>)-3-hydroxy-4-(trimethylammonio)butanoate], a natural compound primarily obtained from meat-containing foods in the diet and/or endogenously synthesized in the body,<sup><xref ref-type="bibr" rid="B194">194</xref></sup> is a necessary nutrient of metabolic oxidation.<sup><xref ref-type="bibr" rid="B195">195</xref></sup> It is required in the transport of medium-chain and long-chain fatty acids (acyl groups) between cell organelles and into the mitochondrial matrix where β-oxidation occurs, and in the removal of intermediate toxic products out of the mitochondria for excretion in urine.<sup><xref ref-type="bibr" rid="B154">154</xref>,<xref ref-type="bibr" rid="B194">194</xref>,<xref ref-type="bibr" rid="B196">196</xref>,<xref ref-type="bibr" rid="B197">197</xref></sup> In combination with carnitine acyltransferases (a family of enzymes that catalyze the reversible transfer of acyl groups between coenzyme A [CoA] and L-carnitine), acyl-carnitine esters are converted into acyl-CoA esters, the active acyl substrate operated on by the mitochondrial enzymes in β-oxidation; in the export of excess acetyl groups from the mitochondria; and in acetylation reactions that regulate gene transcription and enzyme activity.<sup><xref ref-type="bibr" rid="B194">194</xref></sup> L-carnitine has also been shown to confer protection in the prevention of radiation-induced brain and retinal damages.<sup><xref ref-type="bibr" rid="B198">198</xref>,<xref ref-type="bibr" rid="B199">199</xref></sup></p>
</sec>
<sec id="s005">
<title>Nrf2, and Epigenetic Attributes of ALA, L-Carnitine, and Their Conjugated Esters</title>
<p>Retinal diseases and/or damages leading to a substantial loss of retinal neurons can result in visual impairment that may be permanent. The adult mammalian retina has little capacity for regeneration,<sup><xref ref-type="bibr" rid="B200">200</xref>,<xref ref-type="bibr" rid="B201">201</xref></sup> and as noted previously, unmitigated oxidative stresses in ocular tissues can cause irreversible harm to the eye. The Nrf2-Kelch-like ECH-associated protein 1 (Keap1) assembly is one of the main cellular defense systems against oxidative stresses.<sup><xref ref-type="bibr" rid="B110">110</xref>,<xref ref-type="bibr" rid="B169">169</xref>,<xref ref-type="bibr" rid="B202">202</xref></sup> Nrf2 is a key nuclear transcriptional inducer. It couples with ARE in the DNA promoter and synchronizes the transcription of a large number of antioxidant genes, including glutathione-S transferase, glutathione reductase, and thioredoxin reductase.<sup><xref ref-type="bibr" rid="B110">110</xref></sup> Notably, the Nrf2/ARE/Keap1 signaling pathway regulates anti-inflammatory gene expression and inhibits the progression of inflammation.<sup><xref ref-type="bibr" rid="B203">203</xref></sup> Relevant to this discussion, ALA and L-carnitine, separately and/or as a conjugate ester (PMX500FI), are HDAC inhibitors that independently may act to prolong epigenetic gene expression.<sup><xref ref-type="bibr" rid="B31">31</xref></sup></p>
<p>Nrf2 production (<italic>Nfe2l2</italic> gene expression) has been demonstrated (in animals) to decline progressively with age,<sup><xref ref-type="bibr" rid="B141">141</xref>,<xref ref-type="bibr" rid="B166">166</xref></sup> and this may in part account for the retinopathies,<sup><xref ref-type="bibr" rid="B45">45</xref></sup> including macular degeneration, presenting as age-related diseases of the eye.<sup><xref ref-type="bibr" rid="B204">204–206</xref></sup> An imbalance in oxidative stress and antioxidant defense mechanisms contributes to the pathogenesis of both inherited and acquired corneal pathologies<sup><xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref></sup> and to the development of ischemic retinopathies such as diabetic retinopathy and retinopathy of prematurity.<sup><xref ref-type="bibr" rid="B207">207</xref></sup> A study designed to model retinopathies in mice showed that Nrf2 activation reduced the vision-threatening features of oxygen-induced retinopathy, namely vaso-obliteration, neovascularization, and vascular leakage, with potential therapeutic utility.<sup><xref ref-type="bibr" rid="B207">207</xref></sup></p>
<p>Interestingly, activation of the Nrf2 cell defense pathway can also be influenced by diet.<sup><xref ref-type="bibr" rid="B208">208–214</xref></sup> Deregulated nutrient sensing is one of the hallmarks of aging<sup><xref ref-type="bibr" rid="B112">112</xref>,<xref ref-type="bibr" rid="B114">114</xref></sup> and numerous studies link elevated levels of oxidative stress and inflammatory changes in various tissues and organs to a dysbiotic shift in the gut microbiota.<sup><xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B215">215</xref></sup> Kugadas et al.<sup><xref ref-type="bibr" rid="B216">216</xref></sup> suggest that pathogenic bacteria in the gut may affect ocular disease susceptibility, and provide experimental evidence for the existence of a gut-eye axis of immune regulation. A study by Rowan et al.<sup><xref ref-type="bibr" rid="B217">217</xref></sup> discovered that metabolites and microbiota, acting together within a gut-retina axis, appear to protect against diet- and age-induced AMD features—implying that a simple dietary intervention may have complementary use in the treatment of patients with AMD.<sup><xref ref-type="bibr" rid="B218">218</xref>,<xref ref-type="bibr" rid="B219">219</xref></sup> Indeed, metabolomics is an emerging and promising laboratory testing technique for identifying blood profiles associated with AMD across all its stages and severity.<sup><xref ref-type="bibr" rid="B220">220</xref></sup> Microbiome research in general is an aggressive field of study and although the gut microbiome has captured most of the attention,<sup><xref ref-type="bibr" rid="B215">215</xref></sup> the microbiota on the surface of the human eye (ocular microbiome) is drawing increasing interest as a unique and immunoprotective commensal ecosystem.<sup><xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B216">216</xref>,<xref ref-type="bibr" rid="B221">221–224</xref></sup></p>
</sec>
<sec id="s006">
<title>Concluding Remarks</title>
<p>As should be clear at this point, eye disease is a primary medical condition that often requires immediate attention and therapeutic intervention in ageing populations worldwide, not to mention pediatric and young adult patients. Exacerbating the problem is the increasing global burden of diabetes and obesity, along with heart disease, which all lead to significant secondary and tertiary manifestations of ophthalmic distress. Even less serious challenges such as managing dysfunctional tear syndrome continue to frustrate greatly both patients and eye care professionals.<sup><xref ref-type="bibr" rid="B225">225</xref>,<xref ref-type="bibr" rid="B226">226</xref></sup> Therefore, increased interest is manifold in developing innovative new approaches that target various mechanisms and sequelae driving conditions that result in adverse vision. The research and development challenges are even greater given that the varied and extensive terrain of eye diseases is difficult to landscape into a single or even two or three therapeutic themes, although some would say that all roads may ultimately lead to mitochondria.</p>
<p>Thus, in this report, we have attempted to address the burden of eye disease due to mitochondrial dysfunction, including antioxidant, autophagic, epigenetic, mitophagic, and other essential cellular processes that modulate the biomedical end result. In such a light, it is appropriate to single out lipoic acid as a potent known natural activator of these pathways, along with alternative and potentially more effective carnitine conjugates, which together we anticipate could harness the necessary and complete profile of potency, specificity, and biodistribution parameters that are required for improved therapeutic outcomes.</p>
<p>In particular, Nrf2 is an important endogenous protective factor against oxidative stress and essential for supporting and maintaining normal mitochondrial function, especially in neuroretinal and other high energy-demanding tissues. The clinical development of drugs that modulate Nrf2 expression is vigorously being researched as a neuroprotective strategy for treating conditions of oxidative stress, including age-related cataracts and AMD.<sup><xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B110">110</xref>,<xref ref-type="bibr" rid="B169">169</xref>,<xref ref-type="bibr" rid="B202">202</xref>,<xref ref-type="bibr" rid="B227">227–233</xref></sup></p>
<p>Eye disease is reaching epidemic proportions worldwide.<sup><xref ref-type="bibr" rid="B234">234</xref></sup> As yet one more example, it is estimated that the incidence of glaucoma will exceed 100 million cases by 2040,<sup><xref ref-type="bibr" rid="B235">235–238</xref></sup> and most of the people affected will reside in Asia and Africa.<sup><xref ref-type="bibr" rid="B2">2</xref></sup> These healthcare juggernauts are due to primary causes as well as secondary manifestations resulting from metabolic distress in the eye, brain, and elsewhere in the body where energy demanding cell types are resident–again, think mitochondria.<sup><xref ref-type="bibr" rid="B239">239</xref></sup> Ageing populations add to the burden. The revival of interest in developing novel eye disease therapies<sup><xref ref-type="bibr" rid="B237">237–241</xref></sup> is consequently no surprise. We hope that our review convinces even more researchers to join the search for the next generation of safe and effective ophthalmic medicines.</p>
</sec>
</body>
<back>
<sec id="s007" sec-type="ack">
<title>Acknowledgments</title>
<p>We gratefully acknowledge the generous financial support from the MitoCure Foundation and thank Dr. Robert J. Zamboni (McGill University) for his invaluable advice and helpful discussions in the preparation of this article.</p>
</sec>
<sec id="s008">
<title>Authors' Contributions</title>
<p>All authors contributed to the writing of this article and agreed to its final content.</p>
</sec>
<sec id="s009" sec-type="COI-statement">
<title>Author Disclosure Statement</title>
<p>K.S. owns shares in PhenoMatriX, Inc. K.K. and W.H.M. consult with and/or serve on the boards of various biotechnology and pharmaceutical companies from time to time, where they may receive compensation and/or stock options, and they receive compensation from ShangPharma Innovation, Inc., a healthcare venture capital firm.</p>
</sec>
<ref-list content-type="parsed">
<title>References</title>
<ref id="B1">
<label>1</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourne</surname><given-names>RR</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Stevens</surname><given-names>GA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>White</surname><given-names>RA</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Causes of vision loss worldwide, 1990–2010: a systematic analysis</article-title>. <source/>Lancet Glob Health. <year>2013</year>;<volume>1</volume>:<fpage>e339</fpage>–<lpage>e349</lpage><pub-id pub-id-type="pmid">25104599</pub-id></mixed-citation>
</ref>
<ref id="B2">
<label>2</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tham</surname><given-names>Y-C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wong</surname><given-names>TY</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Global prevalence of glaucoma and projections of glaucoma burden through 2040. A systematic review and meta-analysis</article-title>. <source/>Ophthalmology. <year>2014</year>;<volume>121</volume>:<fpage>2081</fpage>–<lpage>2090</lpage><pub-id pub-id-type="pmid">24974815</pub-id></mixed-citation>
</ref>
<ref id="B3">
<label>3</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>WL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Su</surname><given-names>X</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis</article-title>. <source/>Lancet Glob Health. <year>2014</year>;<volume>2</volume>:<fpage>e106</fpage>–<lpage>e116</lpage><pub-id pub-id-type="pmid">25104651</pub-id></mixed-citation>
</ref>
<ref id="B4">
<label>4</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babizhayev</surname><given-names>MA</given-names></name></person-group>
<article-title>Drug design of mitochondria-targeted antioxidants, action, metabolism and perspectives for ophthalmic therapeutics: N-acetylcarnosine codrug treatment platform</article-title>. <source/>Int J Ophthalmol Eye Res. <year>2017</year>;<volume>5</volume>:<fpage>287</fpage>–<lpage>307</lpage></mixed-citation>
</ref>
<ref id="B5">
<label>5</label>
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bowder</surname><given-names>D</given-names></name></person-group> (ed.). <source/>Who Was Who in the Greek World: 776 BC–30 BC. <publisher-name>Cornell University Press</publisher-name>: <publisher-loc>Ithaca, NY</publisher-loc>; p. <fpage>240</fpage>; <year>1982</year></mixed-citation>
</ref>
<ref id="B6">
<label>6</label>
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bertman</surname><given-names>S</given-names></name></person-group>
<source/>The Genesis of Science: The Story of Greek Imagination. <publisher-name>Prometheus Books</publisher-name>: <publisher-loc>Amherst, NY</publisher-loc>; p. <fpage>293</fpage>; <year>2010</year></mixed-citation>
</ref>
<ref id="B7">
<label>7</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Standring</surname><given-names>S</given-names></name></person-group>
<article-title>A brief history of topographical anatomy</article-title>. <source/>J Anat. <year>2016</year>;<volume>229</volume>:<fpage>32</fpage>–<lpage>62</lpage><pub-id pub-id-type="pmid">27278889</pub-id></mixed-citation>
</ref>
<ref id="B8">
<label>8</label>
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Gregory</surname><given-names>RL</given-names></name></person-group>
<source/>Eye and Brain: The Psychology of Seeing, <edition><italic>5th</italic></edition>
<italic>ed</italic>
<publisher-name>Princeton University Press</publisher-name>: <publisher-loc>Princeton, NJ</publisher-loc>; p. <fpage>288</fpage>; <year>2015</year></mixed-citation>
</ref>
<ref id="B9">
<label>9</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aires</surname><given-names>ID</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ambrósio</surname><given-names>AF</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Santiago</surname><given-names>AR</given-names></name></person-group>
<article-title>Modeling human glaucoma: lessons from the in vitro models</article-title>. <source/>Ophthalmic Res. <year>2017</year>;<volume>57</volume>:<fpage>77</fpage>–<lpage>86</lpage><pub-id pub-id-type="pmid">27618367</pub-id></mixed-citation>
</ref>
<ref id="B10">
<label>10</label>
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Moroi</surname><given-names>SE</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lichter</surname><given-names>PR</given-names></name></person-group>
<article-title>Ocular Pharmacology</article-title>. In: <source/>Goodman and Gilman's The Pharmacological Basis of Therapeutics,
<edition>10th</edition> ed. <person-group person-group-type="editor"><name><surname>Hardman</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="editor"><name><surname>Limbrd</surname><given-names>LE</given-names></name></person-group>, (eds.) <publisher-name>McGraw-Hill</publisher-name>: <publisher-loc>New York</publisher-loc>; pp. <fpage>1821</fpage>–<lpage>1845</lpage>; <year>2001</year></mixed-citation>
</ref>
<ref id="B11">
<label>11</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Awwad</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>AHAM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sharma</surname><given-names>G</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Principles of pharmacology in the eye</article-title>. <source/>Br J Pharmacol. <year>2017</year>;<volume>174</volume>:<fpage>4205</fpage>–<lpage>4223</lpage><pub-id pub-id-type="pmid">28865239</pub-id></mixed-citation>
</ref>
<ref id="B12">
<label>12</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vladan</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Panfoli</surname><given-names>I</given-names></name></person-group>
<article-title>Melatonin and abeta, macular degeneration and Alzheimer's Disease: same disease, different outcomes?</article-title>
<source/>MEHDI Ophthalmol J. <year>2012</year>;<volume>1</volume>:<fpage>24</fpage>–<lpage>32</lpage></mixed-citation>
</ref>
<ref id="B13">
<label>13</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>London</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Benhar</surname><given-names>I</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>M</given-names></name></person-group>
<article-title>The retina as a window to the brain—from eye research to CNS disorders</article-title>. <source/>Nat Rev Neurol. <year>2013</year>;<volume>9</volume>:<fpage>44</fpage>–<lpage>53</lpage><pub-id pub-id-type="pmid">23165340</pub-id></mixed-citation>
</ref>
<ref id="B14">
<label>14</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horai</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zárate-Bladés</surname><given-names>CR</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Dillenburg-Pilla</surname><given-names>P</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Microbiota-dependent activation of an autoreactive T cell receptor provokes autoimmunity in an immunologically privileged site</article-title>. <source/>Immunity. <year>2015</year>;<volume>43</volume>:<fpage>343</fpage>–<lpage>353</lpage><pub-id pub-id-type="pmid">26287682</pub-id></mixed-citation>
</ref>
<ref id="B15">
<label>15</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shafaie</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hutter</surname><given-names>V</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Cook</surname><given-names>MT</given-names></name>, <etal>et al.</etal></person-group>
<article-title><italic>In vitro</italic> cell models for ophthalmic drug development applications</article-title>. <source/>BioRes Open Access. <year>2016</year>;<volume>5</volume>:<fpage>94</fpage>–<lpage>108</lpage><pub-id pub-id-type="pmid">27158563</pub-id></mixed-citation>
</ref>
<ref id="B16">
<label>16</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Saltzman</surname><given-names>HA</given-names></name></person-group>
<article-title>Retinal oxygen utilization measured by hyperbaric blackout</article-title>. <source/>Arch Ophthalmol. <year>1964</year>;<volume>72</volume>:<fpage>792</fpage>–<lpage>795</lpage><pub-id pub-id-type="pmid">14205438</pub-id></mixed-citation>
</ref>
<ref id="B17">
<label>17</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong-Riley</surname><given-names>MT</given-names></name></person-group>
<article-title>Energy metabolism of the visual system</article-title>. <source/>Eye Brain. <year>2010</year>;<volume>2</volume>:<fpage>99</fpage>–<lpage>116</lpage><pub-id pub-id-type="pmid">23226947</pub-id></mixed-citation>
</ref>
<ref id="B18">
<label>18</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoang</surname><given-names>QV</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Linsenmeier</surname><given-names>RA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chung</surname><given-names>CK</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Photoreceptor inner segments in monkey and human retina: mitochondrial density, optics, and regional variation</article-title>. <source/>Vis Neurosci. <year>2002</year>;<volume>19</volume>:<fpage>395</fpage>–<lpage>407</lpage><pub-id pub-id-type="pmid">12511073</pub-id></mixed-citation>
</ref>
<ref id="B19">
<label>19</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>Z</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gong</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Löfqvist</surname><given-names>C</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Review: adiponectin in retinopathy</article-title>. <source/>BBA Mol Basis Dis. <year>2016</year>;<volume>1862</volume>:<fpage>1392</fpage>–<lpage>1400</lpage></mixed-citation>
</ref>
<ref id="B20">
<label>20</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McBride</surname><given-names>HM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Neuspiel</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wasiak</surname><given-names>S</given-names></name></person-group>
<article-title>Mitochondria: more than just a powerhouse</article-title>. <source/>Curr Biol. <year>2006</year>;<volume>16</volume>:<fpage>R551</fpage>–<lpage>R560</lpage><pub-id pub-id-type="pmid">16860735</pub-id></mixed-citation>
</ref>
<ref id="B21">
<label>21</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadun</surname><given-names>A</given-names></name></person-group>
<article-title>Acquired mitochondrial impairment as a cause of optic nerve disease</article-title>. <source/>Trans Am Ophthalmol Soc. <year>1998</year>;<volume>96</volume>:<fpage>881</fpage>–<lpage>923</lpage><pub-id pub-id-type="pmid">10360310</pub-id></mixed-citation>
</ref>
<ref id="B22">
<label>22</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chhetri</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gueven</surname><given-names>N</given-names></name></person-group>
<article-title>Targeting mitochondrial function to protect against vision loss</article-title>. <source/>Expert Opin Ther Targets. <year>2016</year>;<volume>20</volume>:<fpage>721</fpage>–<lpage>736</lpage><pub-id pub-id-type="pmid">26761184</pub-id></mixed-citation>
</ref>
<ref id="B23">
<label>23</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gueven</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Nadikudi</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Daniel</surname><given-names>A</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Targeting mitochondrial function to treat optic neuropathy</article-title>. <source/>Mitochondrion. <year>2017</year>;<volume>36</volume>:<fpage>7</fpage>–<lpage>14</lpage><pub-id pub-id-type="pmid">27476756</pub-id></mixed-citation>
</ref>
<ref id="B24">
<label>24</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vallabh</surname><given-names>NA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Romano</surname><given-names>V</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Willoughby</surname><given-names>CE</given-names></name></person-group>
<article-title>Mitochondrial dysfunction and oxidative stress in corneal disease</article-title>. <source/>Mitochondrion. <year>2017</year>;<volume>36</volume>:<fpage>103</fpage>–<lpage>113</lpage><pub-id pub-id-type="pmid">28549842</pub-id></mixed-citation>
</ref>
<ref id="B25">
<label>25</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>DC</given-names></name></person-group>
<article-title>A mitochondrial bioenergetic etiology of disease</article-title>. <source/>J Clin Invest. <year>2013</year>;<volume>123</volume>:<fpage>1405</fpage>–<lpage>1412</lpage><pub-id pub-id-type="pmid">23543062</pub-id></mixed-citation>
</ref>
<ref id="B26">
<label>26</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moos</surname><given-names>WH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Dykens</surname><given-names>JA</given-names></name></person-group>
<article-title>Mitochondrial drugs come of age</article-title>. <source/>Drug Dev Res. <year>2015</year>;<volume>76</volume>:<fpage>57</fpage>–<lpage>60</lpage><pub-id pub-id-type="pmid">25832003</pub-id></mixed-citation>
</ref>
<ref id="B27">
<label>27</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parameshwaran</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Irwin</surname><given-names>MH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Steliou</surname><given-names>K</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Antioxidant-mediated reversal of oxidative damage in mouse modeling of complex I inhibition</article-title>. <source/>Drug Dev Res. <year>2015</year>;<volume>76</volume>:<fpage>72</fpage>–<lpage>81</lpage><pub-id pub-id-type="pmid">25847731</pub-id></mixed-citation>
</ref>
<ref id="B28">
<label>28</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steliou</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Faller</surname><given-names>DV</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Pinkert</surname><given-names>CA</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Bioprotective carnitinoids: lipoic acid, butyrate, and mitochondria-targeting to treat radiation injury</article-title>. <source/>Drug Dev Res. <year>2015</year>;<volume>76</volume>:<fpage>167</fpage>–<lpage>175</lpage><pub-id pub-id-type="pmid">26109467</pub-id></mixed-citation>
</ref>
<ref id="B29">
<label>29</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irwin</surname><given-names>MH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Moos</surname><given-names>WH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Faller</surname><given-names>DV</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Epigenetic treatment of neurodegenerative disorders: Alzheimer and Parkinson diseases</article-title>. <source/>Drug Dev Res. <year>2016</year>;<volume>77</volume>:<fpage>109</fpage>–<lpage>123</lpage><pub-id pub-id-type="pmid">26899010</pub-id></mixed-citation>
</ref>
<ref id="B30">
<label>30</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moos</surname><given-names>WH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Faller</surname><given-names>DV</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Harpp</surname><given-names>DN</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Microbiota and neurological disorders: a gut feeling</article-title>. <source/>BioRes Open Access. <year>2016</year>;<volume>5</volume>:<fpage>137</fpage>–<lpage>145</lpage><pub-id pub-id-type="pmid">27274912</pub-id></mixed-citation>
</ref>
<ref id="B31">
<label>31</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moos</surname><given-names>WH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Maneta</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Pinkert</surname><given-names>CA</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Epigenetic treatment of neuropsychiatric disorders: autism and schizophrenia</article-title>. <source/>Drug Dev Res. <year>2016</year>;<volume>77</volume>:<fpage>53</fpage>–<lpage>72</lpage><pub-id pub-id-type="pmid">26899191</pub-id></mixed-citation>
</ref>
<ref id="B32">
<label>32</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moos</surname><given-names>WH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Pinkert</surname><given-names>CA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Irwin</surname><given-names>MH</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Epigenetic treatment of persistent viral infections</article-title>. <source/>Drug Dev Res. <year>2017</year>;<volume>78</volume>:<fpage>24</fpage>–<lpage>36</lpage><pub-id pub-id-type="pmid">27761936</pub-id></mixed-citation>
</ref>
<ref id="B33">
<label>33</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ardehali</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Balaban</surname><given-names>RS</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Mitochondrial function, biology, and role in disease: a scientific statement from the American Heart Association</article-title>. <source/>Circ Res. <year>2016</year>;<volume>118</volume>:<fpage>1960</fpage>–<lpage>1991</lpage><pub-id pub-id-type="pmid">27126807</pub-id></mixed-citation>
</ref>
<ref id="B34">
<label>34</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fragaki</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chaussenot</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Benoist</surname><given-names>J-F</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Coenzyme Q10 defects may be associated with a deficiency of Q10-independent mitochondrial respiratory chain complexes</article-title>. <source/>Biol Res. <year>2016</year>;<volume>49</volume>:<fpage>4</fpage><pub-id pub-id-type="pmid">26742794</pub-id></mixed-citation>
</ref>
<ref id="B35">
<label>35</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makley</surname><given-names>LN</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>McMenimen</surname><given-names>KA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>DeVree</surname><given-names>BT</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Pharmacological chaperone for α-crystallin partially restores transparency in cataract models</article-title>. <source/>Science. <year>2015</year>;<volume>350</volume>:<fpage>674</fpage>–<lpage>677</lpage><pub-id pub-id-type="pmid">26542570</pub-id></mixed-citation>
</ref>
<ref id="B36">
<label>36</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinlan</surname><given-names>RA</given-names></name></person-group>
<article-title>A new dawn for cataracts</article-title>. <source/>Science. <year>2015</year>;<volume>350</volume>:<fpage>636</fpage>–<lpage>637</lpage><pub-id pub-id-type="pmid">26542559</pub-id></mixed-citation>
</ref>
<ref id="B37">
<label>37</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jarrett</surname><given-names>SG</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lin</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Godley</surname><given-names>BF</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Mitochondrial DNA damage and its potential role in retinal degeneration</article-title>. <source/>Prog Retin Eye Res. <year>2008</year>;<volume>27</volume>:<fpage>596</fpage>–<lpage>607</lpage><pub-id pub-id-type="pmid">18848639</pub-id></mixed-citation>
</ref>
<ref id="B38">
<label>38</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Xu</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Liang</surname><given-names>FQ</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Mitochondrial DNA damage and repair in RPE associated with aging and age-related macular degeneration</article-title>. <source/>Invest Ophthalmol Vis Sci. <year>2011</year>;<volume>52</volume>:<fpage>3521</fpage>–<lpage>3529</lpage><pub-id pub-id-type="pmid">21273542</pub-id></mixed-citation>
</ref>
<ref id="B39">
<label>39</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murakami</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Notomi</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hisatomi</surname><given-names>T</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Photoreceptor cell death and rescue in retinal detachment and degenerations</article-title>. <source/>Prog Retin Eye Res. <year>2013</year>;<volume>37</volume>:<fpage>114</fpage>–<lpage>140</lpage><pub-id pub-id-type="pmid">23994436</pub-id></mixed-citation>
</ref>
<ref id="B40">
<label>40</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dib</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lin</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Maidana</surname><given-names>DE</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Mitochondrial DNA has a pro-inflammatory role in AMD</article-title>. <source/>BBA Mol Cell Res. <year>2015</year>;<volume>1853</volume>:<fpage>2897</fpage>–<lpage>2906</lpage></mixed-citation>
</ref>
<ref id="B41">
<label>41</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cousins</surname><given-names>SW</given-names></name></person-group>
<article-title>Role of mitochondrial dysfunction in dry age-related macular degeneration</article-title>. <source/>Retina Today. <year>2015</year>;<season>May-Jun</season>:<fpage>83</fpage>–<lpage>85</lpage></mixed-citation>
</ref>
<ref id="B42">
<label>42</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Maidana</surname><given-names>DE</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Dib</surname><given-names>B</given-names></name>, <etal>et al.</etal></person-group>
<article-title>miR-17-3p Exacerbates oxidative damage in human retinal pigment epithelial cells</article-title>. <source/>PLoS One. <year>2016</year>;<volume>11</volume>:<fpage>e0160887</fpage><pub-id pub-id-type="pmid">27505139</pub-id></mixed-citation>
</ref>
<ref id="B43">
<label>43</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papanas</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ziegler</surname><given-names>D</given-names></name></person-group>
<article-title>Efficacy of α-lipoic acid in diabetic neuropathy</article-title>. <source/>Expert Opin Pharmacother. <year>2014</year>;<volume>15</volume>:<fpage>2721</fpage>–<lpage>2731</lpage><pub-id pub-id-type="pmid">25381809</pub-id></mixed-citation>
</ref>
<ref id="B44">
<label>44</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kowluru</surname><given-names>RA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kowluru</surname><given-names>AK</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mishra</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Oxidative stress and epigenetic modifications in the pathogenesis of diabetic retinopathy</article-title>. <source/>Prog Retin Eye Res. <year>2015</year>;<volume>48</volume>:<fpage>40</fpage>–<lpage>61</lpage><pub-id pub-id-type="pmid">25975734</pub-id></mixed-citation>
</ref>
<ref id="B45">
<label>45</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kowluru</surname><given-names>RA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mishra</surname><given-names>M</given-names></name></person-group>
<article-title>Epigenetic regulation of redox signaling in diabetic retinopathy: Role of Nrf2</article-title>. <source/>Free Radic Biol Med. <year>2017</year>;<volume>103</volume>:<fpage>155</fpage>–<lpage>164</lpage><pub-id pub-id-type="pmid">28012783</pub-id></mixed-citation>
</ref>
<ref id="B46">
<label>46</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carelli</surname><given-names>V</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ross-Cisneros</surname><given-names>FN</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sadun</surname><given-names>AA</given-names></name></person-group>
<article-title>Mitochondrial dysfunction as a cause of optic neuropathies</article-title>. <source/>Prog in Retin Eye Res. <year>2004</year>;<volume>23</volume>:<fpage>53</fpage>–<lpage>89</lpage><pub-id pub-id-type="pmid">14766317</pub-id></mixed-citation>
</ref>
<ref id="B47">
<label>47</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez</surname><given-names>MIGL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Crowston</surname><given-names>JG</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mackey</surname><given-names>DA</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Emerging mitochondrial therapeutic targets in optic neuropathies</article-title>. <source/>Pharmacol Therapeut. <year>2016</year>;<volume>165</volume>:<fpage>132</fpage>–<lpage>152</lpage></mixed-citation>
</ref>
<ref id="B48">
<label>48</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pelletier</surname><given-names>AL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rojas-Roldan</surname><given-names>L</given-names></name></person-group>
<article-title>Coffin J. Vision loss in older adults</article-title>. <source/>Am Fam Physician. <year>2016</year>;<volume>94</volume>:<fpage>219</fpage>–<lpage>226</lpage><pub-id pub-id-type="pmid">27479624</pub-id></mixed-citation>
</ref>
<ref id="B49">
<label>49</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritch</surname><given-names>R</given-names></name></person-group>
<article-title>Natural compounds: evidence for a protective role in eye disease</article-title>. <source/>Can J Ophthalmol. <year>2007</year>;<volume>42</volume>:<fpage>425</fpage>–<lpage>438</lpage><pub-id pub-id-type="pmid">17508040</pub-id></mixed-citation>
</ref>
<ref id="B50">
<label>50</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>W</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Huang</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C</given-names></name></person-group>
<article-title>Neuroprotective therapies for glaucoma</article-title>. <source/>Drug Des Devel Ther. <year>2015</year>;<volume>9</volume>:<fpage>1469</fpage>–<lpage>1479</lpage></mixed-citation>
</ref>
<ref id="B51">
<label>51</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavlakis</surname><given-names>SG</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hirano</surname><given-names>M</given-names></name></person-group>
<article-title>Mitochondrial diseases: a clinical and molecular history</article-title>. <source/>Pediatr Neurol. <year>2016</year>;<volume>63</volume>:<fpage>3</fpage>–<lpage>5</lpage><pub-id pub-id-type="pmid">27460527</pub-id></mixed-citation>
</ref>
<ref id="B52">
<label>52</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Q</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lesnefsky</surname><given-names>EJ</given-names></name></person-group>
<article-title>A new strategy to treat mitochondrial disease without improvement of mitochondrial function?</article-title>
<source/>eBioMedicine. <year>2017</year>;<volume>18</volume>:<fpage>19</fpage>–<lpage>20</lpage><pub-id pub-id-type="pmid">28330810</pub-id></mixed-citation>
</ref>
<ref id="B53">
<label>53</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Bergen</surname><given-names>NJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chakrabarti</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>O'Neill</surname><given-names>EC</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Mitochondrial disorders and the eye</article-title>. <source/>Eye Brain. <year>2011</year>;<volume>3</volume>:<fpage>29</fpage>–<lpage>47</lpage><pub-id pub-id-type="pmid">28539774</pub-id></mixed-citation>
</ref>
<ref id="B54">
<label>54</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaturvedi</surname><given-names>RK</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Beal</surname><given-names>MF</given-names></name></person-group>
<article-title>Mitochondrial diseases of the brain</article-title>. <source/>Free Radic Biol Med. <year>2013</year>;<volume>63</volume>:<fpage>1</fpage>–<lpage>29</lpage><pub-id pub-id-type="pmid">23567191</pub-id></mixed-citation>
</ref>
<ref id="B55">
<label>55</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamel</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Farrell</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>O'Brien</surname><given-names>C</given-names></name></person-group>
<article-title>Mitochondrial dysfunction in ocular disease: focus on glaucoma</article-title>. <source/>Mitochondrion. <year>2017</year>;<volume>35</volume>:<fpage>44</fpage>–<lpage>53</lpage><pub-id pub-id-type="pmid">28499981</pub-id></mixed-citation>
</ref>
<ref id="B56">
<label>56</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fraser</surname><given-names>JA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Biousse</surname><given-names>V</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Newman</surname><given-names>NJ</given-names></name></person-group>
<article-title>The neuro-ophthalmology of mitochondrial disease</article-title>. <source/>Surv Ophthalmol. <year>2010</year>;<volume>55</volume>:<fpage>299</fpage>–<lpage>334</lpage><pub-id pub-id-type="pmid">20471050</pub-id></mixed-citation>
</ref>
<ref id="B57">
<label>57</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schapira</surname><given-names>AH</given-names></name></person-group>
<article-title>Mitochondrial disease</article-title>. <source/>Lancet. <year>2006</year>;<volume>368</volume>:<fpage>70</fpage>–<lpage>82</lpage><pub-id pub-id-type="pmid">16815381</pub-id></mixed-citation>
</ref>
<ref id="B58">
<label>58</label>
<mixed-citation publication-type="journal"><collab>Mitochondrial Medicine Society's Committee on Diagnosis</collab>, <person-group person-group-type="author"><name><surname>Haas</surname><given-names>RH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Parikh</surname><given-names>S</given-names></name>, <etal>et al.</etal></person-group>
<article-title>The in-depth evaluation of suspected mitochondrial disease</article-title>. <source/>Mol Genet Metab. <year>2008</year>;<volume>94</volume>:<fpage>16</fpage>–<lpage>37</lpage><pub-id pub-id-type="pmid">18243024</pub-id></mixed-citation>
</ref>
<ref id="B59">
<label>59</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimmock</surname><given-names>DP</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lawlor</surname><given-names>MW</given-names></name></person-group>
<article-title>Presentation and diagnostic evaluation of mitochondrial disease</article-title>. <source/>Pediatr Clin. <year>2017</year>;<volume>64</volume>:<fpage>161</fpage>–<lpage>171</lpage></mixed-citation>
</ref>
<ref id="B60">
<label>60</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiMauro</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schon</surname><given-names>EA</given-names></name></person-group>
<article-title>Mitochondrial respiratory-chain diseases</article-title>. <source/>N Engl J Med. <year>2003</year>;<volume>348</volume>:<fpage>2656</fpage>–<lpage>2668</lpage><pub-id pub-id-type="pmid">12826641</pub-id></mixed-citation>
</ref>
<ref id="B61">
<label>61</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>C-C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Traboulsi</surname><given-names>EI</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Parikh</surname><given-names>S</given-names></name></person-group>
<article-title>Ophthalmological findings in 74 patients with mitochondrial disease</article-title>. <source/>Ophthalmic Genet. <year>2017</year>;<volume>38</volume>:<fpage>67</fpage>–<lpage>69</lpage><pub-id pub-id-type="pmid">27029465</pub-id></mixed-citation>
</ref>
<ref id="B62">
<label>62</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grönlund</surname><given-names>MA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Honarvar</surname><given-names>AKS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Andersson</surname><given-names>S</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Ophthalmological findings in children and young adults with genetically verified mitochondrial disease</article-title>. <source/>Br J Ophthalmol. <year>2010</year>;<volume>94</volume>:<fpage>121</fpage>–<lpage>127</lpage><pub-id pub-id-type="pmid">20385529</pub-id></mixed-citation>
</ref>
<ref id="B63">
<label>63</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McFarland</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Taylor</surname><given-names>RW</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Turnbull</surname><given-names>DM</given-names></name></person-group>
<article-title>A neurological perspective on mitochondrial disease</article-title>. <source/>Lancet Neurol. <year>2010</year>;<volume>9</volume>:<fpage>829</fpage>–<lpage>840</lpage><pub-id pub-id-type="pmid">20650404</pub-id></mixed-citation>
</ref>
<ref id="B64">
<label>64</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu-Wai-Man</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Newman</surname><given-names>NJ</given-names></name></person-group>
<article-title>Inherited eye-related disorders due to mitochondrial dysfunction</article-title>. <source/>Hum Mol Genet. <year>2017</year>;<volume>26</volume>:<fpage>R12</fpage>–<lpage>R20</lpage><pub-id pub-id-type="pmid">28481993</pub-id></mixed-citation>
</ref>
<ref id="B65">
<label>65</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherry</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Thompson</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Saptarshi</surname><given-names>N</given-names></name>, <etal>et al.</etal></person-group>
<article-title>A “mitochondria” odyssey</article-title>. <source/>Trends Mol Med. <year>2016</year>;<volume>22</volume>:<fpage>391</fpage>–<lpage>403</lpage></mixed-citation>
</ref>
<ref id="B66">
<label>66</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Youle</surname><given-names>RJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Finkel</surname><given-names>T</given-names></name></person-group>
<article-title>The mitochondrial basis of aging</article-title>. <source/>Mol Cell. <year>2016</year>;<volume>61</volume>:<fpage>654</fpage>–<lpage>666</lpage><pub-id pub-id-type="pmid">26942670</pub-id></mixed-citation>
</ref>
<ref id="B67">
<label>67</label>
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gale</surname><given-names>M </given-names><suffix>Jr</suffix></name></person-group>
<article-title>Mitochondria and antiviral immunity</article-title>. In: <source/>Mitochondria and Cell Death. <person-group person-group-type="editor"><name><surname>Hockenbery</surname><given-names>DM</given-names></name></person-group>, (ed.) <publisher-name>Springer</publisher-name>: <publisher-loc>New York</publisher-loc>; Chapter 10, pp. <fpage>187</fpage>–<lpage>212</lpage> (doi:<pub-id pub-id-type="doi">10.1007/978-1-4939-3612-0_10</pub-id>)</mixed-citation>
</ref>
<ref id="B68">
<label>68</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y</given-names></name></person-group>
<article-title>Regulation of autophagy by mitochondrial phospholipids in health and diseases</article-title>. <source/>BBA Mol Cell Biol Lipid. <year>2017</year>;<volume>1862</volume>:<fpage>114</fpage>–<lpage>129</lpage></mixed-citation>
</ref>
<ref id="B69">
<label>69</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>PA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hou</surname><given-names>X</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hao</surname><given-names>S</given-names></name></person-group>
<article-title>Mitochondrial biogenesis in neurodegeneration</article-title>. <source/>J Neurosci Res. <year>2017</year>;<volume>95</volume>:<fpage>2025</fpage>–<lpage>2029</lpage><pub-id pub-id-type="pmid">28301064</pub-id></mixed-citation>
</ref>
<ref id="B70">
<label>70</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molino</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zemirli</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Codogno</surname><given-names>P</given-names></name>, <etal>et al.</etal></person-group>
<article-title>The journey of the autophagosome through mammalian cell organelles and membranes</article-title>. <source/>J Mol Biol. <year>2017</year>;<volume>429</volume>:<fpage>497</fpage>–<lpage>514</lpage><pub-id pub-id-type="pmid">27986571</pub-id></mixed-citation>
</ref>
<ref id="B71">
<label>71</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ueta</surname><given-names>CB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gomes</surname><given-names>KS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ribeiro</surname><given-names>MA</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Disruption of mitochondrial quality control in peripheral artery disease: new therapeutic opportunities</article-title>. <source/>Pharmacol Res. <year>2017</year>;<volume>115</volume>:<fpage>96</fpage>–<lpage>106</lpage><pub-id pub-id-type="pmid">27876411</pub-id></mixed-citation>
</ref>
<ref id="B72">
<label>72</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boya</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Esteban-Martínez</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Serrano-Puebla</surname><given-names>A</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Autophagy in the eye: development, degeneration, and aging</article-title>. <source/>Prog Retin Eye Res. <year>2016</year>;<volume>55</volume>:<fpage>206</fpage>–<lpage>245</lpage><pub-id pub-id-type="pmid">27566190</pub-id></mixed-citation>
</ref>
<ref id="B73">
<label>73</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holmbeck</surname><given-names>MA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Shadel</surname><given-names>GS</given-names></name></person-group>
<article-title>Mitochondria provide a ‘complex’ solution to a bacterial problem</article-title>. <source/>Nat Immunol. <year>2016</year>;<volume>17</volume>:<fpage>1009</fpage>–<lpage>1010</lpage><pub-id pub-id-type="pmid">27540983</pub-id></mixed-citation>
</ref>
<ref id="B74">
<label>74</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber-Gerlach</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Weber</surname><given-names>F</given-names></name></person-group>
<article-title>Standing on three legs: antiviral activities of RIG-I against influenza viruses</article-title>. <source/>Curr Opin Immunol. <year>2016</year>;<volume>42</volume>:<fpage>71</fpage>–<lpage>75</lpage><pub-id pub-id-type="pmid">27318973</pub-id></mixed-citation>
</ref>
<ref id="B75">
<label>75</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galluzzi</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Pedro</surname><given-names>JMB-S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Levine</surname><given-names>B</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles</article-title>. <source/>Nat Rev Drug Discov. <year>2017</year>;<volume>16</volume>:<fpage>487</fpage>–<lpage>511</lpage><pub-id pub-id-type="pmid">28529316</pub-id></mixed-citation>
</ref>
<ref id="B76">
<label>76</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monlun</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hyernard</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Blanco</surname><given-names>P</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Mitochondria as molecular platforms integrating multiple innate immune signalings</article-title>. <source/>J Mol Biol. <year>2017</year>;<volume>429</volume>:<fpage>1</fpage>–<lpage>13</lpage><pub-id pub-id-type="pmid">27923767</pub-id></mixed-citation>
</ref>
<ref id="B77">
<label>77</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>West</surname><given-names>AP</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Shadel</surname><given-names>GS</given-names></name></person-group>
<article-title>Mitochondrial DNA in innate immune responses and inflammatory pathology</article-title>. <source/>Nat Rev Immunol. <year>2017</year>;<volume>17</volume>:<fpage>363</fpage>–<lpage>375</lpage><pub-id pub-id-type="pmid">28393922</pub-id></mixed-citation>
</ref>
<ref id="B78">
<label>78</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>EL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kelly</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>O'Neill</surname><given-names>LAJ</given-names></name></person-group>
<article-title>Mitochondria are the powerhouses of immunity</article-title>. <source/>Nat Immunol. <year>2017</year>;<volume>18</volume>:<fpage>488</fpage>–<lpage>498</lpage><pub-id pub-id-type="pmid">28418387</pub-id></mixed-citation>
</ref>
<ref id="B79">
<label>79</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Karamanlidis</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tian</surname><given-names>R</given-names></name></person-group>
<article-title>Novel targets for mitochondrial medicine</article-title>. <source/>Sci Transl Med. <year>2016</year>;<volume>8</volume>:<fpage>326rv3</fpage></mixed-citation>
</ref>
<ref id="B80">
<label>80</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinch</surname><given-names>MS</given-names></name></person-group>
<article-title>An analysis of FDA-approved drugs for neurological disorders</article-title>. <source/>Drug Discov Today. <year>2015</year>;<volume>20</volume>:<fpage>1040</fpage>–<lpage>1043</lpage><pub-id pub-id-type="pmid">25681791</pub-id></mixed-citation>
</ref>
<ref id="B81">
<label>81</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griesenauer</surname><given-names>RH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kinch</surname><given-names>MS</given-names></name></person-group>
<article-title>2016 in review: FDA approvals of new molecular entities</article-title>. <source/>Drug Discov Today. <year>2017</year>;<volume>22</volume>:<fpage>1593</fpage>-<lpage>1597</lpage><pub-id pub-id-type="pmid">28687460</pub-id></mixed-citation>
</ref>
<ref id="B82">
<label>82</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hempel</surname><given-names>CM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Werley</surname><given-names>CA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Dempsey</surname><given-names>GT</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Targeting neuronal function for CNS drug discovery</article-title>. <source/>Drug Discov Today. <year>2017</year>;<volume>23</volume>:<fpage>17</fpage>–<lpage>25</lpage></mixed-citation>
</ref>
<ref id="B83">
<label>83</label>
<mixed-citation publication-type="book"><collab>Hippocrates</collab>. ∼460-380 BCE. <article-title>On ancient medicine</article-title>. In: <source/>The Works of Hippocrates. <person-group person-group-type="editor"><name><surname>Dunkas</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="editor"><name><surname>Sioras</surname><given-names>N</given-names></name></person-group> (eds.) <publisher-name>Diachronic Publications</publisher-name>: <publisher-loc>Athens, Hellas</publisher-loc>; pp. <fpage>81</fpage>–<lpage>170</lpage>; <year>1998</year></mixed-citation>
</ref>
<ref id="B84">
<label>84</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shivanvitha</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kamarapu</surname><given-names>P</given-names></name></person-group>
<article-title>Autism–neurodevelopment disorder</article-title>. <source/>Autism Open Access. <year>2016</year>;<volume>6</volume>:<fpage>6</fpage></mixed-citation>
</ref>
<ref id="B85">
<label>85</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sztainberg</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zoghbi</surname><given-names>HY</given-names></name></person-group>
<article-title>Lessons learned from studying syndromic autism spectrum disorders</article-title>. <source/>Nat Neurosci. <year>2016</year>;<volume>19</volume>:<fpage>1408</fpage>–<lpage>1418</lpage><pub-id pub-id-type="pmid">27786181</pub-id></mixed-citation>
</ref>
<ref id="B86">
<label>86</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Karnebeek</surname><given-names>CDM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bowden</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Berry-Kravis</surname><given-names>E</given-names></name></person-group>
<article-title>Treatment of neurogenetic developmental conditions: from 2016 into the future</article-title>. <source/>Pediatr Neurol. <year>2016</year>;<volume>65</volume>:<fpage>1</fpage>–<lpage>13</lpage><pub-id pub-id-type="pmid">27697313</pub-id></mixed-citation>
</ref>
<ref id="B87">
<label>87</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>NR</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Newman</surname><given-names>NJ</given-names></name></person-group>
<article-title>The eye in neurological disease</article-title>. <source/>Lancet. <year>2004</year>;<volume>364</volume>:<fpage>2045</fpage>–<lpage>2054</lpage><pub-id pub-id-type="pmid">15582062</pub-id></mixed-citation>
</ref>
<ref id="B88">
<label>88</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghate</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Vedanarayanan</surname><given-names>V</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kamour</surname><given-names>A</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Optic nerve morphology as marker for disease severity in cerebral palsy of perinatal origin</article-title>. <source/>J Neurol Sci. <year>2016</year>;<volume>368</volume>:<fpage>25</fpage>–<lpage>31</lpage><pub-id pub-id-type="pmid">27538596</pub-id></mixed-citation>
</ref>
<ref id="B89">
<label>89</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>VK</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gupta</surname><given-names>VB</given-names></name></person-group>
<article-title>Using technology, bioinformatics and health informatics approaches to improve learning Experiences in optometry education, research and practice</article-title>. <source/>Healthcare. <year>2016</year>;<volume>4</volume>:<fpage>86</fpage><pub-id pub-id-type="pmid">27343156</pub-id></mixed-citation>
</ref>
<ref id="B90">
<label>90</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Javaid</surname><given-names>FZ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Brenton</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Guo</surname><given-names>L</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Visual and ocular manifestations of Alzheimer's disease and their use as biomarkers for diagnosis and progression</article-title>. <source/>Front Neurol. <year>2016</year>;<volume>7</volume>:<fpage>55</fpage><pub-id pub-id-type="pmid">27148157</pub-id></mixed-citation>
</ref>
<ref id="B91">
<label>91</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>MacKenzie</surname><given-names>KR</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Putluri</surname><given-names>N</given-names></name>, <etal>et al.</etal></person-group>
<article-title>The glia-neuron lactate shuttle and elevated ROS promote lipid synthesis in neurons and lipid droplet accumulation in glia via APOE/D</article-title>. <source/>Cell Metab. <year>2017</year>;<volume>26</volume>:<fpage>719</fpage>–<lpage>737</lpage><pub-id pub-id-type="pmid">28965825</pub-id></mixed-citation>
</ref>
<ref id="B92">
<label>92</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>More</surname><given-names>SS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Beach</surname><given-names>JM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Vince</surname><given-names>R</given-names></name></person-group>
<article-title>Early detection of amyloidopathy in Alzheimer's mice by hyperspectral endoscopy</article-title>. <source/>Invest Ophthalmol Vis Sci. <year>2016</year>;<volume>57</volume>:<fpage>3231</fpage>–<lpage>3238</lpage><pub-id pub-id-type="pmid">27333181</pub-id></mixed-citation>
</ref>
<ref id="B93">
<label>93</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cordeiro</surname><given-names>MF</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Normando</surname><given-names>EM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Cardoso</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Real-time imaging of single neuronal cell apoptosis in patients with glaucoma</article-title>. <source/>Brain. <year>2017</year>;<volume>140</volume>:<fpage>1757</fpage>–<lpage>1767</lpage><pub-id pub-id-type="pmid">28449038</pub-id></mixed-citation>
</ref>
<ref id="B94">
<label>94</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeBuc</surname><given-names>CD</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Somfai</surname><given-names>GM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Koller</surname><given-names>A</given-names></name></person-group>
<article-title>Retinal microvascular network alterations: potential biomarkers of cerebrovascular and neural diseases</article-title>. <source/>Am J Physiol Heart Circ Physiol. <year>2017</year>;<volume>312</volume>:<fpage>H201</fpage>–<lpage>H212</lpage><pub-id pub-id-type="pmid">27923786</pub-id></mixed-citation>
</ref>
<ref id="B95">
<label>95</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koronyo</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Biggs</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Barron</surname><given-names>E</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer's disease</article-title>. <source/>JCI Insight. <year>2017</year>;<volume>2</volume>:<fpage>e93621</fpage></mixed-citation>
</ref>
<ref id="B96">
<label>96</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petzold</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Balcer</surname><given-names>LJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Calabresi</surname><given-names>PA</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis</article-title>. <source/>Lancet Neurol. <year>2017</year>;<volume>16</volume>:<fpage>797</fpage>–<lpage>812</lpage><pub-id pub-id-type="pmid">28920886</pub-id></mixed-citation>
</ref>
<ref id="B97">
<label>97</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stefánsson</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Olafsdottir</surname><given-names>OB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Einarsdottir</surname><given-names>AB</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Retinal oximetry discovers novel biomarkers in retinal and brain diseases</article-title>. <source/>Invest Ophthalmol Vis Sci. <year>2017</year>;<volume>58</volume>:<fpage>BIO227</fpage>–<lpage>BIO233</lpage><pub-id pub-id-type="pmid">28810002</pub-id></mixed-citation>
</ref>
<ref id="B98">
<label>98</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fardeau</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Champion</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Massamba</surname><given-names>N</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Uveitic macular edema</article-title>. <source/>Nat Eye. <year>2016</year>;<volume>30</volume>:<fpage>1277</fpage>–<lpage>1292</lpage></mixed-citation>
</ref>
<ref id="B99">
<label>99</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mammas</surname><given-names>IN</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Greenough</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Theodoridou</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Current views and advances on paediatric virology: an update for paediatric trainees (Review)</article-title>. <source/>Exp Ther Med. <year>2016</year>;<volume>11</volume>: <fpage>6</fpage>–<lpage>14</lpage><pub-id pub-id-type="pmid">26889211</pub-id></mixed-citation>
</ref>
<ref id="B100">
<label>100</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Huang</surname><given-names>YF</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zhang</surname><given-names>WJ</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Ocular diseases: immunological and molecular mechanisms</article-title>. <source/>Int J Ophthalmol. <year>2016</year>;<volume>9</volume>:<fpage>780</fpage>–<lpage>788</lpage><pub-id pub-id-type="pmid">27275439</pub-id></mixed-citation>
</ref>
<ref id="B101">
<label>101</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prakalapakorn</surname><given-names>SG</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Meaney-Delman</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Honein</surname><given-names>MA</given-names></name>, <etal>et al.</etal></person-group>
<article-title>The eyes as a window to improved understanding of the prenatal effects of Zika virus infection</article-title>. <source/>J AAPOS. <year>2017</year>;<fpage>259</fpage>–<lpage>261</lpage><pub-id pub-id-type="pmid">28709964</pub-id></mixed-citation>
</ref>
<ref id="B102">
<label>102</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Z</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Yang</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Azar</surname><given-names>SR</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Viral retinopathy in experimental models of Zika infection</article-title>. <source/>Invest Ophthalmol Vis Sci. <year>2017</year>;<volume>58</volume>:<fpage>4075</fpage>–<lpage>4085</lpage></mixed-citation>
</ref>
<ref id="B103">
<label>103</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGuinness</surname><given-names>MB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Karahalios</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Finger</surname><given-names>RP</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Age-related macular degeneration and mortality: a systematic review and meta-analysis</article-title>. <source/>Ophthalmic Epidemiol. <year>2017</year>;<volume>24</volume>:<fpage>141</fpage>–<lpage>152</lpage><pub-id pub-id-type="pmid">28139151</pub-id></mixed-citation>
</ref>
<ref id="B104">
<label>104</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzarella</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Cole</surname><given-names>J</given-names></name></person-group>
<article-title>All eyes on neurodegenerative disease</article-title>. <source/>Rev Optom. <year>2016</year>;<volume>153</volume>(<issue>2</issue>):<fpage>42</fpage>–<lpage>52</lpage></mixed-citation>
</ref>
<ref id="B105">
<label>105</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McClintic</surname><given-names>BR</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>McClintic</surname><given-names>JI</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bisognano</surname><given-names>JD</given-names></name>, <etal>et al.</etal></person-group>
<article-title>The relationship between retinal microvascular abnormalities and coronary heart disease: a review</article-title>. <source/>Am J Med. <year>2010</year>;<volume>123</volume>:<fpage>374.e1</fpage>–<lpage>374.e7</lpage></mixed-citation>
</ref>
<ref id="B106">
<label>106</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dykens</surname><given-names>JA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Carroll</surname><given-names>AK</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wiley</surname><given-names>S</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Photoreceptor preservation in the S334ter model of retinitis pigmentosa by a novel estradiol analog</article-title>. <source/>Biochem Pharmacol. <year>2004</year>;<volume>68</volume>:<fpage>1971</fpage>–<lpage>1984</lpage><pub-id pub-id-type="pmid">15476668</pub-id></mixed-citation>
</ref>
<ref id="B107">
<label>107</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sengillo</surname><given-names>JD</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Justus</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tsai</surname><given-names>Y-T</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Gene and cell-based therapies for inherited retinal disorders: an update</article-title>. <source/>Am J Med Genet Part C Semin Med Genet. <year>2016</year>;<volume>172C</volume>:<fpage>349</fpage>–<lpage>366</lpage></mixed-citation>
</ref>
<ref id="B108">
<label>108</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garatachea</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Pareja-Galeano</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sanchis-Gomar</surname><given-names>F</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Exercise attenuates the major hallmarks of aging</article-title>. <source/>Rejuvenation Res. <year>2015</year>;<volume>18</volume>:<fpage>57</fpage>–<lpage>89</lpage><pub-id pub-id-type="pmid">25431878</pub-id></mixed-citation>
</ref>
<ref id="B109">
<label>109</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da Costa</surname><given-names>JP</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Vitorino</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Silva</surname><given-names>GM</given-names></name>, <etal>et al.</etal></person-group>
<article-title>A synopsis on aging—theories, mechanisms and future prospects</article-title>. <source/>Ageing Res Rev. <year>2016</year>;<volume>29</volume>:<fpage>90</fpage>–<lpage>112</lpage><pub-id pub-id-type="pmid">27353257</pub-id></mixed-citation>
</ref>
<ref id="B110">
<label>110</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X-F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hao</surname><given-names>J-L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Xie</surname><given-names>T</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Nrf2 as a target for prevention of age-related and diabetic cataracts by against oxidative stress</article-title>. <source/>Aging Cell. <year>2017</year>;<volume>16</volume>:<fpage>934</fpage>–<lpage>942</lpage><pub-id pub-id-type="pmid">28722304</pub-id></mixed-citation>
</ref>
<ref id="B111">
<label>111</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diot</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Morten</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Poulton</surname><given-names>J</given-names></name></person-group>
<article-title>Mitophagy plays a central role in mitochondrial ageing</article-title>. <source/>Mamm Genome. <year>2016</year>;<volume>27</volume>:<fpage>381</fpage>–<lpage>395</lpage><pub-id pub-id-type="pmid">27352213</pub-id></mixed-citation>
</ref>
<ref id="B112">
<label>112</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernández-Aguilera</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Fernández-Arroyo</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Cuyàs</surname><given-names>E</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Epigenetics and nutrition-related epidemics of metabolic diseases: current perspectives and challenges</article-title>. <source/>Food Chem Toxicol. <year>2016</year>;<volume>96</volume>:<fpage>191</fpage>–<lpage>204</lpage><pub-id pub-id-type="pmid">27503834</pub-id></mixed-citation>
</ref>
<ref id="B113">
<label>113</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodes</surname><given-names>RJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sierra</surname><given-names>F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Austad</surname><given-names>SN</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Disease drivers of aging</article-title>. <source/>Ann NY Acad Sci. <year>2016</year>;<volume>1386</volume>:<fpage>45</fpage>–<lpage>68</lpage><pub-id pub-id-type="pmid">27943360</pub-id></mixed-citation>
</ref>
<ref id="B114">
<label>114</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peleg</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Feller</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ladurner</surname><given-names>AG</given-names></name>, <etal>et al.</etal></person-group>
<article-title>The metabolic impact on histone acetylation and transcription in ageing</article-title>. <source/>Trends Biochem Sci. <year>2016</year>;<volume>41</volume>:<fpage>700</fpage>–<lpage>711</lpage><pub-id pub-id-type="pmid">27283514</pub-id></mixed-citation>
</ref>
<ref id="B115">
<label>115</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sebastián</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Palacín</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zorzano</surname><given-names>A</given-names></name></person-group>
<article-title>Mitochondrial dynamics: coupling mitochondrial fitness with healthy aging</article-title>. <source/>Trends Mol Med. <year>2017</year>;<volume>23</volume>:<fpage>201</fpage>–<lpage>215</lpage><pub-id pub-id-type="pmid">28188102</pub-id></mixed-citation>
</ref>
<ref id="B116">
<label>116</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Qi</surname><given-names>Y</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Mitochondrial cAMP signaling</article-title>. <source/>Cell Mol Life Sci. <year>2016</year>;<volume>73</volume>:<fpage>4577</fpage>–<lpage>4590</lpage><pub-id pub-id-type="pmid">27233501</pub-id></mixed-citation>
</ref>
<ref id="B117">
<label>117</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Towers</surname><given-names>CG</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Thorburn</surname><given-names>A</given-names></name></person-group>
<article-title>Therapeutic targeting of autophagy</article-title>. <source/>EBioMedicine. <year>2016</year>;<volume>14</volume>:<fpage>15</fpage>–<lpage>23</lpage><pub-id pub-id-type="pmid">28029600</pub-id></mixed-citation>
</ref>
<ref id="B118">
<label>118</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boya</surname><given-names>P</given-names></name></person-group>
<article-title>Why autophagy is good for retinal ganglion cells?</article-title>
<source/>Nat Eye. <year>2017</year>;<volume>31</volume>:<fpage>185</fpage>–<lpage>190</lpage></mixed-citation>
</ref>
<ref id="B119">
<label>119</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lesnefsky</surname><given-names>EJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chen</surname><given-names>Q</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tandler</surname><given-names>B</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Mitochondrial dysfunction and myocardial ischemia-reperfusion: implications for novel therapies</article-title>. <source/>Annu Rev Pharmacol Toxicol. <year>2017</year>;<volume>57</volume>:<fpage>535</fpage>–<lpage>565</lpage><pub-id pub-id-type="pmid">27860548</pub-id></mixed-citation>
</ref>
<ref id="B120">
<label>120</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ploumi</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Daskalaki</surname><given-names>I</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tavernarakis</surname><given-names>N</given-names></name></person-group>
<article-title>Mitochondrial biogenesis and clearance: a balancing act</article-title>. <source/>FEBS J. <year>2017</year>;<volume>284</volume>:<fpage>183</fpage>–<lpage>195</lpage><pub-id pub-id-type="pmid">27462821</pub-id></mixed-citation>
</ref>
<ref id="B121">
<label>121</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matenia</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mandelkow</surname><given-names>EM</given-names></name></person-group>
<article-title>Emerging modes of PINK1 signaling: another task for MARK2</article-title>. <source/>Front Mol Neurosci. <year>2014</year>;<volume>7</volume>:<fpage>37</fpage><pub-id pub-id-type="pmid">24847206</pub-id></mixed-citation>
</ref>
<ref id="B122">
<label>122</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pickrell</surname><given-names>AM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Youle</surname><given-names>RJ</given-names></name></person-group>
<article-title>The roles of PINK1, Parkin, and mitochondrial fidelity in Parkinson's disease</article-title>. <source/>Neuron. <year>2015</year>;<volume>85</volume>:<fpage>257</fpage>–<lpage>273</lpage><pub-id pub-id-type="pmid">25611507</pub-id></mixed-citation>
</ref>
<ref id="B123">
<label>123</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laforge</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rodrigues</surname><given-names>V</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Silvestre</surname><given-names>R</given-names></name>, <etal>et al.</etal></person-group>
<article-title>NF-κB pathway controls mitochondrial dynamics</article-title>. <source/>Cell Death Differ. <year>2016</year>;<volume>23</volume>:<fpage>89</fpage>–<lpage>98</lpage><pub-id pub-id-type="pmid">26024391</pub-id></mixed-citation>
</ref>
<ref id="B124">
<label>124</label>
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Narendra</surname><given-names>DP</given-names></name></person-group>
<article-title>Clinical features of Parkinsonism due to PARKIN and PINK1 mutations, the human phenotype</article-title>. In: <source/>Mitochondrial Mechanisms of Degeneration and Repair in Parkinson's Disease. <person-group person-group-type="editor"><name><surname>Buhlman</surname><given-names>LM</given-names></name></person-group>, (ed.) <publisher-name>Springer International Publishing</publisher-name>: <publisher-loc>Switzerland</publisher-loc>; Chapter 8 pp.<fpage>159</fpage>–<lpage>182</lpage>; <year>2016</year></mixed-citation>
</ref>
<ref id="B125">
<label>125</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altshuler-Keylin</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kajimura</surname><given-names>S</given-names></name></person-group>
<article-title>Mitochondrial homeostasis in adipose tissue remodeling</article-title>. <source/>Sci Signal. <year>2017</year>;<volume>10</volume>:<fpage>eaai9248</fpage><pub-id pub-id-type="pmid">28246203</pub-id></mixed-citation>
</ref>
<ref id="B126">
<label>126</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Georgakopoulos</surname><given-names>ND</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wells</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Campanella</surname><given-names>M</given-names></name></person-group>
<article-title>The pharmacological regulation of cellular mitophagy</article-title>. <source/>Nat Chem Biol. <year>2017</year>;<volume>13</volume>:<fpage>136</fpage>–<lpage>146</lpage><pub-id pub-id-type="pmid">28103219</pub-id></mixed-citation>
</ref>
<ref id="B127">
<label>127</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melentijevic</surname><given-names>I</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Toth</surname><given-names>ML</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Arnold</surname><given-names>ML</given-names></name>, <etal>et al.</etal></person-group>
<article-title><italic>C. elegans</italic> neurons jettison protein aggregates and mitochondria under neurotoxic stress</article-title>. <source/>Nature. <year>2017</year>;<volume>542</volume>:<fpage>367</fpage>–<lpage>371</lpage><pub-id pub-id-type="pmid">28178240</pub-id></mixed-citation>
</ref>
<ref id="B128">
<label>128</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nũnez-Figueredo</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Pardo-Andreu</surname><given-names>GL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ramírez-Sánchez</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Antioxidant effects of JM-20 on rat brain mitochondria and synaptosomes: Mitoprotection against Ca<sup>2+</sup>-induced mitochondrial impairment</article-title>. <source/>Brain Res Bull. <year>2014</year>;<volume>109</volume>:<fpage>68</fpage>–<lpage>76</lpage><pub-id pub-id-type="pmid">25305343</pub-id></mixed-citation>
</ref>
<ref id="B129">
<label>129</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>González-Durruthy</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Monserrat</surname><given-names>JM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Alberici</surname><given-names>LC</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Mitoprotective activity of oxidized carbon nanotubes against mitochondrial swelling induced in multiple experimental conditions and predictions with new expected-value perturbation theory</article-title>. <source/>RSC Adv. <year>2015</year>;<volume>5</volume>:<fpage>103229</fpage>–<lpage>103245</lpage></mixed-citation>
</ref>
<ref id="B130">
<label>130</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>González-Durruthy</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Castro</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Nunes</surname><given-names>SM</given-names></name>, <etal>et al.</etal></person-group>
<article-title>QSPR/QSAR-based Perturbation Theory approach and mechanistic electrochemical assays on carbon nanotubes with optimal properties against mitochondrial Fenton reaction experimentally induced by Fe<sup>2+</sup>-overload</article-title>. <source/>Carbon. <year>2017</year>;<volume>115</volume>:<fpage>312</fpage>–<lpage>330</lpage></mixed-citation>
</ref>
<ref id="B131">
<label>131</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bachurin</surname><given-names>SO</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bovina</surname><given-names>EV</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ustyugov</surname><given-names>AA</given-names></name></person-group>
<article-title>Drugs in clinical trials for Alzheimer's disease: the major trends</article-title>. <source/>Med Res Rev. <year>2017</year>;<volume>37</volume>:<fpage>1186</fpage>–<lpage>1225</lpage><pub-id pub-id-type="pmid">28084618</pub-id></mixed-citation>
</ref>
<ref id="B132">
<label>132</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bading</surname><given-names>H</given-names></name></person-group>
<article-title>Therapeutic targeting of the pathological triad of extrasynaptic NMDA receptor signaling in neurodegenerations</article-title>. <source/>J Exp Med. <year>2017</year>;<volume>214</volume>:<fpage>569</fpage>–<lpage>578</lpage><pub-id pub-id-type="pmid">28209726</pub-id></mixed-citation>
</ref>
<ref id="B133">
<label>133</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palikaras</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tavernarakis</surname><given-names>N</given-names></name></person-group>
<article-title>Mitochondrial homeostasis: the interplay between mitophagy and mitochondrial biogenesis</article-title>. <source/>Exp Gerontol. <year>2014</year>;<volume>56</volume>:<fpage>182</fpage>–<lpage>188</lpage><pub-id pub-id-type="pmid">24486129</pub-id></mixed-citation>
</ref>
<ref id="B134">
<label>134</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Z</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ren</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Y</given-names></name>, <etal>et al.</etal></person-group>
<article-title>PINK1 and Parkin cooperatively protect neurons against constitutively active TRP channel-induced retinal degeneration in <italic>Drosophila</italic></article-title>. <source/>Cell Death Dis. <year>2016</year>;<volume>7</volume>:<fpage>e2179</fpage><pub-id pub-id-type="pmid">27054334</pub-id></mixed-citation>
</ref>
<ref id="B135">
<label>135</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brennan</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Khoury</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kantorow</surname><given-names>M</given-names></name></person-group>
<article-title>Parkin elimination of mitochondria is important for maintenance of lens epithelial cell ROS levels and survival upon oxidative stress exposure</article-title>. <source/>BBA Mol Basis Dis. <year>2017</year>;<volume>1863</volume>:<fpage>21</fpage>–<lpage>32</lpage></mixed-citation>
</ref>
<ref id="B136">
<label>136</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>TD</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sergin</surname><given-names>I</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Target acquired: selective autophagy in cardiometabolic disease</article-title>. <source/>Sci Signal. <year>2017</year>;<volume>10</volume>:<fpage>eaag2298</fpage><pub-id pub-id-type="pmid">28246200</pub-id></mixed-citation>
</ref>
<ref id="B137">
<label>137</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>H-U</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Friis</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tait</surname><given-names>SWG</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Retrograde signaling from autophagy modulates stress responses</article-title>. <source/>Sci Signal. <year>2017</year>;<volume>10</volume>:<fpage>eaag2791</fpage><pub-id pub-id-type="pmid">28246201</pub-id></mixed-citation>
</ref>
<ref id="B138">
<label>138</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Taegtmeyer</surname><given-names>H</given-names></name></person-group>
<article-title>Too much or not enough of a good thing–the Janus faces of autophagy in cardiac fuel and protein homeostasis</article-title>. <source/>J Mol Cell Cardiol. <year>2015</year>;<volume>84</volume>:<fpage>223</fpage>–<lpage>226</lpage><pub-id pub-id-type="pmid">25771142</pub-id></mixed-citation>
</ref>
<ref id="B139">
<label>139</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esner</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Graifer</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lleonart</surname><given-names>ME</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Targeting cancer cells through antibiotics-induced mitochondrial dysfunction requires autophagy inhibition</article-title>. <source/>Cancer Lett. <year>2017</year>;<volume>384</volume>:<fpage>60</fpage>–<lpage>69</lpage><pub-id pub-id-type="pmid">27693455</pub-id></mixed-citation>
</ref>
<ref id="B140">
<label>140</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravanan</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Srikumar</surname><given-names>F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Talwar</surname><given-names>P</given-names></name></person-group>
<article-title>Autophagy: the spotlight for cellular stress responses</article-title>. <source/>Life Sci. <year>2017</year>;<volume>188</volume>:<fpage>53</fpage>–<lpage>67</lpage><pub-id pub-id-type="pmid">28866100</pub-id></mixed-citation>
</ref>
<ref id="B141">
<label>141</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stern</surname><given-names>M</given-names></name></person-group>
<article-title>Evidence that a mitochondrial death spiral underlies antagonistic pleiotropy</article-title>. <source/>Aging Cell. <year>2017</year>;<volume>16</volume>:<fpage>435</fpage>–<lpage>443</lpage><pub-id pub-id-type="pmid">28185435</pub-id></mixed-citation>
</ref>
<ref id="B142">
<label>142</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoner</surname><given-names>MW</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Thapa</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zhang</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group>
<article-title>α-Lipoic acid promotes α-tubulin hyperacetylation and blocks the turnover of mitochondria through mitophagy</article-title>. <source/>Biochem J. <year>2016</year>;<volume>473</volume>:<fpage>1821</fpage>–<lpage>1830</lpage><pub-id pub-id-type="pmid">27099338</pub-id></mixed-citation>
</ref>
<ref id="B143">
<label>143</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SY</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Oh</surname><given-names>JS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rho</surname><given-names>JH</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Retinal pigment epithelial cells undergoing mitotic catastrophe are vulnerable to autophagy inhibition</article-title>. <source/>Nat Cell Death Dis. <year>2014</year>;<volume>5</volume>:<fpage>e1303</fpage></mixed-citation>
</ref>
<ref id="B144">
<label>144</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cronan</surname><given-names>JE</given-names></name></person-group>
<article-title>Assembly of lipoic acid on its cognate enzymes: an extraordinary and essential biosynthetic pathway</article-title>. <source/>Microbiol Mol Biol Rev. <year>2016</year>;<volume>80</volume>:<fpage>429</fpage>–<lpage>450</lpage><pub-id pub-id-type="pmid">27074917</pub-id></mixed-citation>
</ref>
<ref id="B145">
<label>145</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van de Mark</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chen</surname><given-names>JS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Steliou</surname><given-names>K</given-names></name>, <etal>et al.</etal></person-group>
<article-title>α-Lipoic acid induces p27Kip-dependent cell cycle arrest in non-transformed cell lines and apoptosis in tumor cell lines</article-title>. <source/>J Cell Physiol. <year>2003</year>;<volume>194</volume>:<fpage>325</fpage>–<lpage>340</lpage><pub-id pub-id-type="pmid">12548552</pub-id></mixed-citation>
</ref>
<ref id="B146">
<label>146</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayr</surname><given-names>JA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Feichtinger</surname><given-names>RG</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tort</surname><given-names>F</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Lipoic acid biosynthesis defects</article-title>. <source/>J Inherit Metab Dis. <year>2014</year>;<volume>37</volume>:<fpage>553</fpage>–<lpage>563</lpage><pub-id pub-id-type="pmid">24777537</pub-id></mixed-citation>
</ref>
<ref id="B147">
<label>147</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>MJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Obrosova</surname><given-names>I</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Cao</surname><given-names>X</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy</article-title>. <source/>Diabetes. <year>2000</year>;<volume>49</volume>:<fpage>1006</fpage>–<lpage>1015</lpage><pub-id pub-id-type="pmid">10866054</pub-id></mixed-citation>
</ref>
<ref id="B148">
<label>148</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scangas</surname><given-names>GA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bleier</surname><given-names>BS</given-names></name></person-group>
<article-title>Anosmia: differential diagnosis, evaluation, and management</article-title>. <source/>Am J Rhinol Allergy. <year>2017</year>;<volume>31</volume>:<fpage>e3</fpage>–<lpage>e7</lpage></mixed-citation>
</ref>
<ref id="B149">
<label>149</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tibullo</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Volti</surname><given-names>GL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Giallongo</surname><given-names>C</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Biochemical and clinical relevance of alpha lipoic acid: antioxidant and anti-inflammatory activity, molecular pathways and therapeutic potential</article-title>. <source/>Inflamm Res. <year>2017</year>;<volume>66</volume>:<fpage>947</fpage>–<lpage>959</lpage><pub-id pub-id-type="pmid">28676917</pub-id></mixed-citation>
</ref>
<ref id="B150">
<label>150</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirani</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Okuda</surname><given-names>DT</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Stüve</surname><given-names>O</given-names></name></person-group>
<article-title>Therapeutic advances and future prospects in progressive forms of multiple sclerosis</article-title>. <source/>Neurotherapeutics. <year>2016</year>;<volume>13</volume>:<fpage>58</fpage>–<lpage>69</lpage><pub-id pub-id-type="pmid">26729332</pub-id></mixed-citation>
</ref>
<ref id="B151">
<label>151</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garrett</surname><given-names>NE</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Malcangio</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Dewhurst</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Alpha-lipoic acid corrects neuropeptide deficits in diabetic rats via induction of trophic support</article-title>. <source/>Neurosci Lett. <year>1997</year>;<volume>222</volume>:<fpage>191</fpage>–<lpage>194</lpage><pub-id pub-id-type="pmid">9148247</pub-id></mixed-citation>
</ref>
<ref id="B152">
<label>152</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hounsom</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Corder</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Patel</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Oxidative stress participates in the breakdown of neuronal phenotype in experimental diabetic neuropathy</article-title>. <source/>Diabetologia. <year>2001</year>;<volume>44</volume>:<fpage>424</fpage>–<lpage>428</lpage><pub-id pub-id-type="pmid">11357471</pub-id></mixed-citation>
</ref>
<ref id="B153">
<label>153</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coppey</surname><given-names>LJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gellett</surname><given-names>JS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Davidson</surname><given-names>EP</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve</article-title>. <source/>Diabetes. <year>2001</year>;<volume>50</volume>:<fpage>1927</fpage>–<lpage>1937</lpage><pub-id pub-id-type="pmid">11473057</pub-id></mixed-citation>
</ref>
<ref id="B154">
<label>154</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steliou</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Perrine</surname><given-names>SP</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Faller</surname><given-names>DV</given-names></name></person-group>
<article-title>Lactic acid in cancer and mitochondrial disease</article-title>. <source/>Drug Dev Res. <year>2009</year>;<volume>70</volume>:<fpage>499</fpage>–<lpage>511</lpage></mixed-citation>
</ref>
<ref id="B155">
<label>155</label>
<mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Steliou</surname><given-names>K</given-names></name></person-group>
<source/>Mitochondria-Targeting Antioxidant Therapeutics. US Patent. 8,741,853; <year>2014</year></mixed-citation>
</ref>
<ref id="B156">
<label>156</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garner</surname><given-names>WH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Garner</surname><given-names>MH</given-names></name></person-group>
<article-title>Protein disulfide levels and lens elasticity modulation: applications for presbyopia</article-title>. <source/>Invest Ophthalmol Vis Sci. <year>2016</year>;<volume>57</volume>:<fpage>2851</fpage>–<lpage>2863</lpage><pub-id pub-id-type="pmid">27233034</pub-id></mixed-citation>
</ref>
<ref id="B157">
<label>157</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sozio</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>D'Aurizio</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Iannitelli</surname><given-names>A</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Ibuprofen and lipoic acid diamides as potential codrugs with neuroprotective activity</article-title>. <source/>Arch Pharm Chem Life Sci. <year>2010</year>;<volume>343</volume>:<fpage>133</fpage>–<lpage>142</lpage></mixed-citation>
</ref>
<ref id="B158">
<label>158</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cacciatore</surname><given-names>I</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Marinelli</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Fornasari</surname><given-names>E</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Novel NSAID-derived drugs for the potential treatment of Alzheimer's disease</article-title>. <source/>Int J Mol Sci. <year>2016</year>;<volume>17</volume>:<fpage>1035</fpage></mixed-citation>
</ref>
<ref id="B159">
<label>159</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosini</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Simoni</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bartolini</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Exploiting the lipoic acid structure in the search for novel multitarget ligands against Alzheimer's disease</article-title>. <source/>Eur J Med Chem. <year>2011</year>;<volume>46</volume>:<fpage>5435</fpage>–<lpage>5442</lpage><pub-id pub-id-type="pmid">21924801</pub-id></mixed-citation>
</ref>
<ref id="B160">
<label>160</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zielonka</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Joseph</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sikora</surname><given-names>A</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Mitochondria-targeted triphenylphosphonium-based compounds: syntheses, mechanisms of action, and therapeutic and diagnostic applications</article-title>. <source/>Chem Rev. <year>2017</year>;<volume>117</volume>:<fpage>10043</fpage>–<lpage>10120</lpage><pub-id pub-id-type="pmid">28654243</pub-id></mixed-citation>
</ref>
<ref id="B161">
<label>161</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Connell</surname><given-names>BJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Saleh</surname><given-names>MC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rajagopal</surname><given-names>D</given-names></name>, <etal>et al.</etal></person-group>
<article-title>UPEI-400, a conjugate of lipoic acid and scopoletin, mediates neuroprotection in a rat model of ischemia/reperfusion</article-title>. <source/>Food Chem Toxicol. <year>2017</year>;<volume>100</volume>:<fpage>175</fpage>–<lpage>182</lpage><pub-id pub-id-type="pmid">28017701</pub-id></mixed-citation>
</ref>
<ref id="B162">
<label>162</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zhou</surname><given-names>X</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group>
<article-title>α-Lipoic acid protects against the cytotoxicity and oxidative stress induced by cadmium in HepG2 cells through regeneration of glutathione by glutathione reductase via Nrf2/ARE signaling pathway</article-title>. <source/>Environ Toxicol Pharmacol. <year>2016</year>;<volume>45</volume>:<fpage>274</fpage>–<lpage>281</lpage><pub-id pub-id-type="pmid">27343752</pub-id></mixed-citation>
</ref>
<ref id="B163">
<label>163</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zee</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bose</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zee</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group>
<article-title>α-Lipoic acid treatment prevents cystine urolithiasis in a mouse model of cystinuria</article-title>. <source/>Nat Med. <year>2017</year>;<volume>23</volume>:<fpage>288</fpage>–<lpage>290</lpage><pub-id pub-id-type="pmid">28165480</pub-id></mixed-citation>
</ref>
<ref id="B164">
<label>164</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuadrado</surname><given-names>A</given-names></name></person-group>
<article-title>NRF2 in neurodegenerative diseases</article-title>. <source/>Curr Opin Toxicol. <year>2016</year>;<volume>1</volume>:<fpage>46</fpage>–<lpage>53</lpage></mixed-citation>
</ref>
<ref id="B165">
<label>165</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tabei</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Murotomi</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Umeno</surname><given-names>A</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Antioxidant properties of 5-hydroxy-4-phenyl-butenolide via activation of Nrf2/ARE signaling pathway</article-title>. <source/>Food Chem Toxicol. <year>2017</year>;<volume>107</volume>:<fpage>129</fpage>–<lpage>137</lpage><pub-id pub-id-type="pmid">28655653</pub-id></mixed-citation>
</ref>
<ref id="B166">
<label>166</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loboda</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Damulewicz</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Pyza</surname><given-names>E</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism</article-title>. <source/>Cell Mol Life Sci. <year>2016</year>;<volume>73</volume>:<fpage>3221</fpage>–<lpage>3247</lpage><pub-id pub-id-type="pmid">27100828</pub-id></mixed-citation>
</ref>
<ref id="B167">
<label>167</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Al-Moujahed</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bouzika</surname><given-names>P</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Atorvastatin promotes phagocytosis and attenuates pro-inflammatory response in human retinal pigment epithelial cells</article-title>. <source/>Sci Rep. <year>2017</year>;<volume>7</volume>:<fpage>2329</fpage><pub-id pub-id-type="pmid">28539592</pub-id></mixed-citation>
</ref>
<ref id="B168">
<label>168</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vavvas</surname><given-names>DG</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Daniels</surname><given-names>AB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kapsala</surname><given-names>Z</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Regression of some high-risk features of age-related macular degeneration (AMD) in patients receiving intensive statin treatment</article-title>. <source/>EBioMedicine. <year>2016</year>;<volume>5</volume>:<fpage>198</fpage>–<lpage>203</lpage><pub-id pub-id-type="pmid">27077128</pub-id></mixed-citation>
</ref>
<ref id="B169">
<label>169</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W-J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wu</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Nrf2 protects photoreceptor cells from photo-oxidative stress induced by blue light</article-title>. <source/>Exp Eye Res. <year>2017</year>;<volume>154</volume>:<fpage>151</fpage>–<lpage>158</lpage><pub-id pub-id-type="pmid">27923559</pub-id></mixed-citation>
</ref>
<ref id="B170">
<label>170</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasegawa</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Inafuku</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mulki</surname><given-names>L</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Cytochrome P450 monooxygenase lipid metabolites are significant second messengers in the resolution of choroidal neovascularization</article-title>. <source/>Proc Natl Acad Sci U S A. <year>2017</year>;<volume>114</volume>:<fpage>E7545</fpage>–<lpage>E7553</lpage><pub-id pub-id-type="pmid">28827330</pub-id></mixed-citation>
</ref>
<ref id="B171">
<label>171</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laíns</surname><given-names>I</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Miller</surname><given-names>JB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Park</surname><given-names>DH</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Structural changes associated with delayed dark adaptation in age-related macular degeneration</article-title>. <source/>Ophthalmology. <year>2017</year>;<volume>124</volume>:<fpage>1340</fpage>–<lpage>1352</lpage><pub-id pub-id-type="pmid">28501377</pub-id></mixed-citation>
</ref>
<ref id="B172">
<label>172</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fine</surname><given-names>SL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Berger</surname><given-names>JW</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Maguire</surname><given-names>MG</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Age-related macular degeneration</article-title>. <source/>N Engl J Med. <year>2000</year>;<volume>342</volume>:<fpage>483</fpage>–<lpage>492</lpage><pub-id pub-id-type="pmid">10675430</pub-id></mixed-citation>
</ref>
<ref id="B173">
<label>173</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Jong</surname><given-names>PT</given-names></name></person-group>
<article-title>Age-related macular degeneration</article-title>. <source/>N Engl J Med. <year>2006</year>;<volume>355</volume>:<fpage>1474</fpage>–<lpage>1485</lpage><pub-id pub-id-type="pmid">17021323</pub-id></mixed-citation>
</ref>
<ref id="B174">
<label>174</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jager</surname><given-names>RD</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mieler</surname><given-names>WF</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Miller</surname><given-names>JW</given-names></name></person-group>
<article-title>Age-related macular degeneration</article-title>. <source/>N Engl J Med. <year>2008</year>;<volume>358</volume>:<fpage>2606</fpage>–<lpage>2617</lpage><pub-id pub-id-type="pmid">18550876</pub-id></mixed-citation>
</ref>
<ref id="B175">
<label>175</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voloboueva</surname><given-names>LA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Suh</surname><given-names>JH</given-names></name>, <etal>et al.</etal></person-group>
<article-title>(R)-α-Lipoic acid protects retinal pigment epithelial cells from oxidative damage</article-title>. <source/>Invest Ophthalmol Vis Sci. <year>2005</year>;<volume>46</volume>:<fpage>4302</fpage>–<lpage>4310</lpage><pub-id pub-id-type="pmid">16249512</pub-id></mixed-citation>
</ref>
<ref id="B176">
<label>176</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biewenga</surname><given-names>GP</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Haenen</surname><given-names>GRMM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bast</surname><given-names>A</given-names></name></person-group>
<article-title>The pharmacology of the antioxidant lipoic acid</article-title>. <source/>Gen Pharmacol. <year>1997</year>;<volume>29</volume>:<fpage>315</fpage>–<lpage>331</lpage><pub-id pub-id-type="pmid">9378235</pub-id></mixed-citation>
</ref>
<ref id="B177">
<label>177</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlson</surname><given-names>DA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Smith</surname><given-names>AR</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Fischer</surname><given-names>SJ</given-names></name>, <etal>et al.</etal></person-group>
<article-title>The plasma pharmacokinetics of R-(+)-lipoic acid administered as sodium R-(+)-lipoate to healthy human subjects</article-title>. <source/>Altern Med Rev. <year>2007</year>;<volume>12</volume>:<fpage>343</fpage>–<lpage>351</lpage><pub-id pub-id-type="pmid">18069903</pub-id></mixed-citation>
</ref>
<ref id="B178">
<label>178</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorąca</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Huk-Kolega</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Piechota</surname><given-names>A</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Lipoic acid—biological activity and therapeutic potential</article-title>. <source/>Pharmacol Rep. <year>2011</year>;<volume>63</volume>:<fpage>849</fpage>–<lpage>858</lpage><pub-id pub-id-type="pmid">22001972</pub-id></mixed-citation>
</ref>
<ref id="B179">
<label>179</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keith</surname><given-names>DJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Butler</surname><given-names>JA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bemer</surname><given-names>B</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Age and gender dependent bioavailability of R- and R,S- α-lipoic acid: a pilot study</article-title>. <source/>Pharmacol Res. <year>2012</year>;<volume>66</volume>:<fpage>199</fpage>–<lpage>206</lpage><pub-id pub-id-type="pmid">22609537</pub-id></mixed-citation>
</ref>
<ref id="B180">
<label>180</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hermann</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Niebch</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Borbe</surname><given-names>HO</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Enantioselective pharmacokinetics and bioavailability of α-lipoic acid formulations in healthy volunteers</article-title>. <source/>Eur J Pharm Sci. <year>1996</year>;<volume>4</volume>:<fpage>167</fpage>–<lpage>174</lpage></mixed-citation>
</ref>
<ref id="B181">
<label>181</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolson</surname><given-names>GL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Settineri</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ellithorpe</surname><given-names>RR</given-names></name></person-group>
<article-title>Neurodegenerative and fatiguing illnesses, infections and mitochondrial dysfunction: use of natural supplements to improve mitochondrial function</article-title>. <source/>Funct Food Health Dis. <year>2014</year>;<volume>4</volume>:<fpage>23</fpage>–<lpage>65</lpage></mixed-citation>
</ref>
<ref id="B182">
<label>182</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziegler</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Low</surname><given-names>PA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Freeman</surname><given-names>R</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Predictors of improvement and progression of diabetic polyneuropathy following treatment with α-lipoic acid for 4 years in the NATHAN 1 trial</article-title>. <source/>J Diabetes Complications. <year>2016</year>;<volume>30</volume>:<fpage>350</fpage>–<lpage>356</lpage><pub-id pub-id-type="pmid">26651260</pub-id></mixed-citation>
</ref>
<ref id="B183">
<label>183</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lillvis</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Seyoum</surname><given-names>B</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Peripheral blood mitochondrial DNA damage as a potential noninvasive biomarker of diabetic retinopathy</article-title>. <source/>Invest Ophthalmol Vis Sci. <year>2016</year>;<volume>57</volume>:<fpage>4035</fpage>–<lpage>4044</lpage><pub-id pub-id-type="pmid">27494345</pub-id></mixed-citation>
</ref>
<ref id="B184">
<label>184</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nebbioso</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Federici</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rusciano</surname><given-names>D</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Oxidative stress in preretinopathic diabetes subjects and antioxidants</article-title>. <source/>Diabetes Technol Ther. <year>2012</year>;<volume>14</volume>:<fpage>257</fpage>–<lpage>263</lpage><pub-id pub-id-type="pmid">22044044</pub-id></mixed-citation>
</ref>
<ref id="B185">
<label>185</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jiang</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wei</surname><given-names>Y</given-names></name>, <etal>et al.</etal></person-group>
<article-title>α-Lipoic acid treatment improves vision-related quality of life in patients with dry age-related macular degeneration</article-title>. <source/>Tohoku J Exp Med. <year>2016</year>;<volume>240</volume>:<fpage>209</fpage>–<lpage>214</lpage><pub-id pub-id-type="pmid">27840374</pub-id></mixed-citation>
</ref>
<ref id="B186">
<label>186</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Pu</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Effect of alpha lipoic acid on retinal ganglion cell survival in an optic nerve crush model</article-title>. <source/>Mol Vis. <year>2016</year>;<volume>22</volume>:<fpage>1122</fpage>–<lpage>1136</lpage><pub-id pub-id-type="pmid">27703307</pub-id></mixed-citation>
</ref>
<ref id="B187">
<label>187</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>DL</given-names></name></person-group>
<article-title>Effect of oral alpha lipoic acid in preventing the genesis of canine diabetic cataract: a preliminary study</article-title>. <source/>Vet Sci. <year>2017</year>;<volume>4</volume>:<fpage>18</fpage></mixed-citation>
</ref>
<ref id="B188">
<label>188</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osborne</surname><given-names>NN</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Álvarez</surname><given-names>CN</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>del Olmo Aguado</surname><given-names>S</given-names></name></person-group>
<article-title>Targeting mitochondrial dysfunction as in aging and glaucoma</article-title>. <source/>Drug Discov Today. <year>2014</year>;<volume>19</volume>:<fpage>1613</fpage>–<lpage>1622</lpage><pub-id pub-id-type="pmid">24880106</pub-id></mixed-citation>
</ref>
<ref id="B189">
<label>189</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apostolova</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Victor</surname><given-names>VM</given-names></name></person-group>
<article-title>Molecular strategies for targeting antioxidants to mitochondria: therapeutic implications</article-title>. <source/>Antioxid Redox Signal. <year>2015</year>;<volume>22</volume>:<fpage>686</fpage>–<lpage>729</lpage><pub-id pub-id-type="pmid">25546574</pub-id></mixed-citation>
</ref>
<ref id="B190">
<label>190</label>
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Guzman-Villanueva</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Weissig</surname><given-names>V</given-names></name></person-group>
<article-title>Delivery of biologically active molecules to mitochondria</article-title>. In: <source/>Mitochondrial Mechanisms of Degeneration and Repair in Parkinson's Disease. <person-group person-group-type="editor"><name><surname>Buhlman</surname><given-names>LM</given-names></name></person-group> (ed.) <publisher-name>Springer International Publishing</publisher-name>; <publisher-loc>Switzerland</publisher-loc>; Chapter 13 pp. <fpage>255</fpage>–<lpage>267</lpage>; <year>2016</year></mixed-citation>
</ref>
<ref id="B191">
<label>191</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romano</surname><given-names>KA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Martinez-del Campo</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kasahara</surname><given-names>K</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Metabolic, epigenetic, and transgenerational effects of gut bacterial choline consumption</article-title>. <source/>Cell Host Microbe. <year>2017</year>;<volume>22</volume>:<fpage>279</fpage>–<lpage>290</lpage><pub-id pub-id-type="pmid">28844887</pub-id></mixed-citation>
</ref>
<ref id="B192">
<label>192</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mindel</surname><given-names>JS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mittag</surname><given-names>TW</given-names></name></person-group>
<article-title>Choline acetyltransferase in ocular tissues of rabbits, cats, cattle, and man</article-title>. <source/>Invest Ophthalmol Vis Sci. <year>1976</year>;<volume>15</volume>:<fpage>808</fpage>–<lpage>814</lpage></mixed-citation>
</ref>
<ref id="B193">
<label>193</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fgaier</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mustafa</surname><given-names>IHI</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Awad</surname><given-names>AAR</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Modeling the interaction between β-amyloid aggregates and choline acetyltransferase activity and its relation with cholinergic dysfunction through two-enzyme/two-compartment model</article-title>. <source/>Comput Math Methods Med. <year>2015</year>;<volume>2015</volume>:<fpage>923762</fpage><pub-id pub-id-type="pmid">26413144</pub-id></mixed-citation>
</ref>
<ref id="B194">
<label>194</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adeva-Andany</surname><given-names>MM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Calvo-Castro</surname><given-names>I</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Fernández- Fernández</surname><given-names>C</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Significance of L-carnitine for human health</article-title>. <source/>IUBMB Life. <year>2017</year>;<volume>69</volume>:<fpage>578</fpage>–<lpage>594</lpage><pub-id pub-id-type="pmid">28653367</pub-id></mixed-citation>
</ref>
<ref id="B195">
<label>195</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>G</given-names></name></person-group>
<article-title>The discovery of a vitamin role for carnitine: the first 50 years</article-title>. <source/>J Nuer. <year>2006</year>;<volume>136</volume>:<fpage>2131</fpage>–<lpage>2134</lpage></mixed-citation>
</ref>
<ref id="B196">
<label>196</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Longo</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Frigeni</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Pasquali</surname><given-names>M</given-names></name></person-group>
<article-title>Carnitine transport and fatty acid oxidation</article-title>. <source/>BBA Mol Cell Res. <year>2016</year>;<volume>1863</volume>:<fpage>2422</fpage>–<lpage>2435</lpage></mixed-citation>
</ref>
<ref id="B197">
<label>197</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mock</surname><given-names>DM</given-names></name></person-group>
<article-title>Biotin: from nutrition to therapeutics</article-title>. <source/>J Nutr. <year>2017</year>;<volume>147</volume>:<fpage>1487</fpage>–<lpage>1492</lpage><pub-id pub-id-type="pmid">28701385</pub-id></mixed-citation>
</ref>
<ref id="B198">
<label>198</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sezen</surname><given-names>O</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ertekin</surname><given-names>MV</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Demircan</surname><given-names>B</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Vitamin E and L-carnitine, separately or in combination, in the prevention of radiation-induced brain and retinal damages</article-title>. <source/>Neurosurg Rev. <year>2008</year>;<volume>31</volume>:<fpage>205</fpage>–<lpage>213</lpage><pub-id pub-id-type="pmid">18259790</pub-id></mixed-citation>
</ref>
<ref id="B199">
<label>199</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Virmani</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Diedenhofen</surname><given-names>A</given-names></name></person-group>
<article-title>The possible mechanisms involved in the protection strategies against radiation-induced cellular damage by carnitines</article-title>. <source/>Int J Clin Med. <year>2015</year>;<volume>6</volume>:<fpage>71</fpage>–<lpage>80</lpage></mixed-citation>
</ref>
<ref id="B200">
<label>200</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crair</surname><given-names>MC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mason</surname><given-names>CA</given-names></name></person-group>
<article-title>Reconnecting eye to brain</article-title>. <source/>J Neurosci. <year>2016</year>;<volume>36</volume>:<fpage>10707</fpage>–<lpage>10722</lpage><pub-id pub-id-type="pmid">27798125</pub-id></mixed-citation>
</ref>
<ref id="B201">
<label>201</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jorstad</surname><given-names>NL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wilken</surname><given-names>MS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Grimes</surname><given-names>WN</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Stimulation of functional neuronal regeneration from Müller glia in adult mice</article-title>. <source/>Nature. <year>2017</year>;<volume>548</volume>:<fpage>103</fpage>–<lpage>107</lpage><pub-id pub-id-type="pmid">28746305</pub-id></mixed-citation>
</ref>
<ref id="B202">
<label>202</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Su</surname><given-names>W</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wan</surname><given-names>T</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Sodium butyrate regulates Th17/Treg cell balance to ameliorate uveitis via the Nrf2/HO-1 pathway</article-title>. <source/>Biochem Pharmacol. <year>2017</year>;<volume>142</volume>:<fpage>111</fpage>–<lpage>119</lpage><pub-id pub-id-type="pmid">28684304</pub-id></mixed-citation>
</ref>
<ref id="B203">
<label>203</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>SMU</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Luo</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Namani</surname><given-names>A</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Nrf2 signaling pathway: pivotal roles in inflammation</article-title>. <source/>BBA Mol Basis Dis. <year>2017</year>;<volume>1863</volume>:<fpage>585</fpage>–<lpage>597</lpage></mixed-citation>
</ref>
<ref id="B204">
<label>204</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Z</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Age-related retinopathy in NRF2-deficient mice</article-title>. <source/>PLoS One. <year>2011</year>;<volume>6</volume>:<fpage>e19456</fpage><pub-id pub-id-type="pmid">21559389</pub-id></mixed-citation>
</ref>
<ref id="B205">
<label>205</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foresti</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bucolo</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Platania</surname><given-names>CMB</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Nrf2 activators modulate oxidative stress responses and bioenergetics profiles of human retinal epithelial cells cultured in normal or high glucose conditions</article-title>. <source/>Pharmacol Res. <year>2015</year>;<volume>99</volume>:<fpage>296</fpage>–<lpage>307</lpage><pub-id pub-id-type="pmid">26188148</pub-id></mixed-citation>
</ref>
<ref id="B206">
<label>206</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>JB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tsubota</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Apte</surname><given-names>RS</given-names></name></person-group>
<article-title>A glimpse at the aging eye</article-title>. <source/>Nat Aging Mech of Dis. <year>2016</year>;<volume>2</volume>:<fpage>16003</fpage></mixed-citation>
</ref>
<ref id="B207">
<label>207</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deliyanti</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lee</surname><given-names>JY</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Petratos</surname><given-names>S</given-names></name>, <etal>et al.</etal></person-group>
<article-title>A potent Nrf2 activator, dh404, bolsters antioxidant capacity in glial cells and attenuates ischaemic retinopathy</article-title>. <source/>Clin Sci. <year>2016</year>;<volume>130</volume>:<fpage>1375</fpage>–<lpage>1387</lpage><pub-id pub-id-type="pmid">27005782</pub-id></mixed-citation>
</ref>
<ref id="B208">
<label>208</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>KN</given-names></name></person-group>
<article-title>Simultaneous activation of Nrf2 and elevation of dietary and endogenous antioxidant chemicals for cancer prevention in humans</article-title>. <source/>J Am Coll Nutr. <year>2016</year>;<volume>35</volume>:<fpage>175</fpage>–<lpage>184</lpage><pub-id pub-id-type="pmid">26151600</pub-id></mixed-citation>
</ref>
<ref id="B209">
<label>209</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hou</surname><given-names>D-X</given-names></name></person-group>
<article-title>Multiple regulations of Keap1/Nrf2 system by dietary phytochemicals</article-title>. <source/>Mol Nutr Food Res. <year>2016</year>;<volume>60</volume>:<fpage>1731</fpage>–<lpage>1755</lpage><pub-id pub-id-type="pmid">27523917</pub-id></mixed-citation>
</ref>
<ref id="B210">
<label>210</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senger</surname><given-names>DR</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Li</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jaminet</surname><given-names>S-C</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Activation of the Nrf2 cell defense pathway by ancient foods: disease prevention by important molecules and microbes lost from the modern western diet</article-title>. <source/>PLoS One. <year>2016</year>;<volume>11</volume>:<fpage>e0148042</fpage><pub-id pub-id-type="pmid">26885667</pub-id></mixed-citation>
</ref>
<ref id="B211">
<label>211</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinkova-Kostova</surname><given-names>AT</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Fahey</surname><given-names>JW</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kostov</surname><given-names>RV</given-names></name>, <etal>et al.</etal></person-group>
<article-title>KEAP1 and Done? Targeting the NRF2 pathway with sulforaphane</article-title>. <source/>Trends Food Sci Technol. <year>2017</year>;<volume>69</volume>:<fpage>257</fpage>–<lpage>269</lpage><pub-id pub-id-type="pmid">29242678</pub-id></mixed-citation>
</ref>
<ref id="B212">
<label>212</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fahey</surname><given-names>JW</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wade</surname><given-names>KL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wehage</surname><given-names>SL</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Stabilized sulforaphane for clinical use: phytochemical delivery efficiency</article-title>. <source/>Mol Nutr Food Res. <year>2017</year>;<volume>61</volume>:<fpage>1600766</fpage></mixed-citation>
</ref>
<ref id="B213">
<label>213</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lee</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Choi</surname><given-names>B-R</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Sulforaphane epigenetically enhances neuronal BDNF expression and TrkB signaling pathways</article-title>. <source/>Mol Nutr Food Res. <year>2017</year>;<volume>61</volume>:<fpage>1600194</fpage></mixed-citation>
</ref>
<ref id="B214">
<label>214</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Negrette-Guzmán</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Huerta-Yepez</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Vega</surname><given-names>MI</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Sulforaphane induces differential modulation of mitochondrial biogenesis and dynamics in normal cells and tumor cells</article-title>. <source/>Food Chem Toxicol. <year>2017</year>;<volume>100</volume>:<fpage>90</fpage>–<lpage>102</lpage><pub-id pub-id-type="pmid">27993529</pub-id></mixed-citation>
</ref>
<ref id="B215">
<label>215</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kodukula</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Faller</surname><given-names>DV</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Harpp</surname><given-names>DN</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Gut microbiota &amp; salivary diagnostics: the mouth is salivating to tell us something</article-title>. <source/>BioRes Open Access. <year>2017</year>;<volume>6</volume>:<fpage>123</fpage>–<lpage>132</lpage><pub-id pub-id-type="pmid">29098118</pub-id></mixed-citation>
</ref>
<ref id="B216">
<label>216</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kugadas</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wright</surname><given-names>Q</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Geddes-McAlister</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Role of microbiota in strengthening ocular mucosal barrier function through secretory IgA</article-title>. <source/>Invest Ophthalmol Vis Sci. <year>2017</year>;<volume>58</volume>:<fpage>4593</fpage>–<lpage>4600</lpage><pub-id pub-id-type="pmid">28892827</pub-id></mixed-citation>
</ref>
<ref id="B217">
<label>217</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowan</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jiang</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Korem</surname><given-names>T</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Involvement of a gut-retina axis in protection against dietary glycemia-induced age-related macular degeneration</article-title>. <source/>Proc Natl Acad Sci U S A. <year>2017</year>;<volume>112</volume>:<fpage>E4472</fpage>–<lpage>E4481</lpage></mixed-citation>
</ref>
<ref id="B218">
<label>218</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bandello</surname><given-names>F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sacconi</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Querques</surname><given-names>L</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Recent advances in the management of dry age-related macular degeneration: a review</article-title>. <source/>F1000Research. <year>2017</year>;<volume>6</volume>:<fpage>245</fpage><pub-id pub-id-type="pmid">28529701</pub-id></mixed-citation>
</ref>
<ref id="B219">
<label>219</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>AY</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Butt</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chew</surname><given-names>E</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Cost-effectiveness of age-related macular degeneration study supplements in the UK: combined trial and real-world outcomes data</article-title>. <source/>Br J Ophthalmol. <year>2017</year> [Epub ahead of print]; DOI: <pub-id pub-id-type="doi">10.1136/bjophthalmol-2017-310939</pub-id></mixed-citation>
</ref>
<ref id="B220">
<label>220</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laíns</surname><given-names>I</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kelly</surname><given-names>RS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Miller</surname><given-names>JB</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Human plasma metabolomics study across all stages of age-related macular degeneration identifies potential lipid biomarkers</article-title>. <source/>Ophthalmology. <year>2017</year> [Epub ahead of print]; DOI: <pub-id pub-id-type="doi">10.1016/j.ophtha.2017.08.008</pub-id></mixed-citation>
</ref>
<ref id="B221">
<label>221</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Price</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Albert</surname><given-names>L</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Changes in the eye microbiota associated with contact lens wearing</article-title>. <source/>mBio. <year>2016</year>;<volume>7</volume>:<fpage>e00198</fpage>–<lpage>16</lpage><pub-id pub-id-type="pmid">27006462</pub-id></mixed-citation>
</ref>
<ref id="B222">
<label>222</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reyes</surname><given-names>NJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Saban</surname><given-names>DR</given-names></name></person-group>
<article-title>A commencement for eye commensals</article-title>. <source/>Immunity. <year>2017</year>;<volume>47</volume>:<fpage>6</fpage>–<lpage>8</lpage><pub-id pub-id-type="pmid">28723553</pub-id></mixed-citation>
</ref>
<ref id="B223">
<label>223</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>St. Leger</surname><given-names>AJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Desai</surname><given-names>JV</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Drummond</surname><given-names>RA</given-names></name>, <etal>et al.</etal></person-group>
<article-title>An ocular commensal protects against corneal infection by driving an interleukin-17 response from mucosal γδ T cells</article-title>. <source/>Immunity. <year>2017</year>;<volume>47</volume>:<fpage>148</fpage>–<lpage>158</lpage><pub-id pub-id-type="pmid">28709803</pub-id></mixed-citation>
</ref>
<ref id="B224">
<label>224</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang X</surname><given-names>M V</given-names></name></person-group>J, <person-group person-group-type="author"><name><surname>Qu</surname><given-names>Y</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Dry eye management: targeting the ocular surface microenvironment</article-title>. <source/>Int J Mol Sci. <year>2017</year>;<volume>18</volume>:<fpage>1398</fpage></mixed-citation>
</ref>
<ref id="B225">
<label>225</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milner</surname><given-names>MS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Beckman</surname><given-names>KA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Luchs</surname><given-names>JI</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Dysfunctional tear syndrome: dry eye disease and associated tear film disorders–new strategies for diagnosis and treatment</article-title>. <source/>Curr Opin Ophthalmol. <year>2017</year>;<volume>28</volume>(<issue>Suppl 1</issue>):<fpage>3</fpage><pub-id pub-id-type="pmid">27653608</pub-id></mixed-citation>
</ref>
<ref id="B226">
<label>226</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrade</surname><given-names>AS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Salomon</surname><given-names>TB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Behling</surname><given-names>CS</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Alpha-lipoic acid restores tear production in an animal model of dry eye</article-title>. <source/>Exp Eye Res. <year>2014</year>;<volume>120</volume>:<fpage>1</fpage>–<lpage>9</lpage><pub-id pub-id-type="pmid">24394592</pub-id></mixed-citation>
</ref>
<ref id="B227">
<label>227</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>M-C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ji</surname><given-names>J-A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Z-Y</given-names></name>, <etal>et al.</etal></person-group>
<article-title>The Keap1–Nrf2–ARE pathway as a potential preventive and therapeutic target: an update</article-title>. <source/>Med Res Rev. <year>2016</year>;<volume>36</volume>:<fpage>924</fpage>–<lpage>963</lpage><pub-id pub-id-type="pmid">27192495</pub-id></mixed-citation>
</ref>
<ref id="B228">
<label>228</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bresciani</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Missineo</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gallo</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1)</article-title>. <source/>Arch Biochem Biophys. <year>2017</year>;<volume>631</volume>:<fpage>31</fpage>–<lpage>41</lpage><pub-id pub-id-type="pmid">28801166</pub-id></mixed-citation>
</ref>
<ref id="B229">
<label>229</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campolo</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Casili</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Biundo</surname><given-names>F</given-names></name>, <etal>et al.</etal></person-group>
<article-title>The neuroprotective effect of dimethyl fumarate in an MPTP-mouse model of Parkinson's disease: involvement of reactive oxygen species/nuclear factor-κB/nuclear transcription factor related to NF-E2</article-title>. <source/>Antioxid Redox Signal. <year>2017</year>;<volume>27</volume>:<fpage>453</fpage>–<lpage>471</lpage><pub-id pub-id-type="pmid">28006954</pub-id></mixed-citation>
</ref>
<ref id="B230">
<label>230</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Periyasamy</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Shinohara</surname><given-names>T</given-names></name></person-group>
<article-title>Age-related cataracts: role of unfolded protein response, Ca<sup>2+</sup> mobilization, epigenetic DNA modifications, and loss of Nrf2/Keap1 dependent cytoprotection</article-title>. <source/>Prog Retin Eye Res. <year>2017</year>;<volume>60</volume>:<fpage>1</fpage>–<lpage>19</lpage><pub-id pub-id-type="pmid">28864287</pub-id></mixed-citation>
</ref>
<ref id="B231">
<label>231</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vu</surname><given-names>KT</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hulleman</surname><given-names>JD</given-names></name></person-group>
<article-title>An inducible form of Nrf2 confers enhanced protection against acute oxidative stresses in RPE cells</article-title>. <source/>Exp Eye Res. <year>2017</year>;<volume>164</volume>:<fpage>31</fpage>–<lpage>36</lpage><pub-id pub-id-type="pmid">28782506</pub-id></mixed-citation>
</ref>
<ref id="B232">
<label>232</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simoni</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Serafini</surname><given-names>MM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Caporaso</surname><given-names>R</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Targeting the Nrf2/amyloid-beta liaison in Alzheimer's disease: a rational approach</article-title>. <source/>ACS Chem Neurosci. <year>2017</year>;<volume>8</volume>:<fpage>1618</fpage>–<lpage>1627</lpage><pub-id pub-id-type="pmid">28421738</pub-id></mixed-citation>
</ref>
<ref id="B233">
<label>233</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satoh</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Stalder</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>McKercher</surname><given-names>SR</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Nrf2 and HSF-1 pathway activation via hydroquinone-based proelectrophilic small molecules is regulated by electrochemical oxidation potential</article-title>. <source/>ASN Neuro. <year>2015</year>;<volume>7</volume>:<fpage>1</fpage></mixed-citation>
</ref>
<ref id="B234">
<label>234</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Callaghan</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Cassidy</surname><given-names>PS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Humphries</surname><given-names>P</given-names></name></person-group>
<article-title>Open-angle glaucoma: therapeutically targeting the extracellular matrix of the conventional outflow pathway</article-title>. <source/>Exp Opin Ther Targets. <year>2017</year>;<volume>21</volume>:<fpage>1037</fpage>–<lpage>1050</lpage></mixed-citation>
</ref>
<ref id="B235">
<label>235</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flaxman</surname><given-names>SR</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bourne</surname><given-names>RRA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Resnikoff</surname><given-names>S</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis</article-title>. <source/>Lancet Glob Health. <year>2017</year>;<volume>5</volume>:<fpage>e1221</fpage>–<lpage>e1234</lpage><pub-id pub-id-type="pmid">29032195</pub-id></mixed-citation>
</ref>
<ref id="B236">
<label>236</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrés-Guerrero</surname><given-names>V</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bravo-Osuna</surname><given-names>I</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Pilar Pastoriza</surname><given-names>P</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Novel technologies for the delivery of ocular therapeutics in glaucoma</article-title>. <source/>J Drug Deliv Sci Technol. <year>2017</year>;<volume>42</volume>:<fpage>181</fpage>–<lpage>192</lpage></mixed-citation>
</ref>
<ref id="B237">
<label>237</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livne-Bar</surname><given-names>I</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wei</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Liu</surname><given-names>H-H</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Astrocyte-derived lipoxins A4 and B4 promote neuroprotection from acute and chronic injury</article-title>. <source/>J Clin Invest. <year>2017</year>;<volume>127</volume>:<fpage>4403</fpage>–<lpage>4414</lpage></mixed-citation>
</ref>
<ref id="B238">
<label>238</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonas</surname><given-names>JB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Aung</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bourne</surname><given-names>RR</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Glaucoma</article-title>. <source/>Lancet. <year>2017</year>;<volume>390</volume>:<fpage>2083</fpage>–<lpage>2093</lpage><pub-id pub-id-type="pmid">28844475</pub-id></mixed-citation>
</ref>
<ref id="B239">
<label>239</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lefevere</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Toft-Kehler</surname><given-names>AK</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Vohra</surname><given-names>R</given-names></name></person-group>
<article-title>et al. Mitochondrial dysfunction underlying outer retinal diseases</article-title>. <source/>Mitochondrion. <year>2017</year>;<volume>36</volume>:<fpage>66</fpage>–<lpage>76</lpage><pub-id pub-id-type="pmid">28365408</pub-id></mixed-citation>
</ref>
<ref id="B240">
<label>240</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abd</surname><given-names>AJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kanwar</surname><given-names>RK</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kanwar</surname><given-names>JR</given-names></name></person-group>
<article-title>Aged macular degeneration: current therapeutics for management and promising new drug candidates</article-title>. <source/>Drug Discov Today. <year>2017</year>;<volume>22</volume>:<fpage>1671</fpage>–<lpage>1679</lpage><pub-id pub-id-type="pmid">28782687</pub-id></mixed-citation>
</ref>
<ref id="B241">
<label>241</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kudisch</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>da Silva</surname><given-names>NRK</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent</article-title>. <source/>J Control Release. <year>2017</year>;<volume>269</volume>:<fpage>45</fpage>–<lpage>51</lpage><pub-id pub-id-type="pmid">29127001</pub-id></mixed-citation>
</ref>
</ref-list>
<ref-list>
<p><bold>Cite this article as:</bold> Moos WH, Faller DV, Glavas IP, Harpp DN, Irwin MH, Kanara I, Pinkert CA, Powers WR, Steliou K, Vavvas DG, Kodukula K (2017) Epigenetic treatment of neurodegenerative ophthalmic disorders: an eye toward the future, <italic>BioResearch Open Access</italic> 6:1, 169–181, DOI: 10.1089/biores.2017.0036.</p>
</ref-list>
<glossary>
<title>Abbreviations Used</title>
<def-list>
<def-item>
<term id="G1">AD</term>
<def>
<p>Alzheimer's disease</p>
</def>
</def-item>
<def-item>
<term id="G2">ALA</term>
<def>
<p>α-lipoic acid</p>
</def>
</def-item>
<def-item>
<term id="G3">AMD</term>
<def>
<p>age-related macular degeneration</p>
</def>
</def-item>
<def-item>
<term id="G4">ARE</term>
<def>
<p>antioxidant response element</p>
</def>
</def-item>
<def-item>
<term id="G5">ATP</term>
<def>
<p>adenosine triphosphate</p>
</def>
</def-item>
<def-item>
<term id="G6">CNS</term>
<def>
<p>central nervous system</p>
</def>
</def-item>
<def-item>
<term id="G7">CoA</term>
<def>
<p>coenzyme A</p>
</def>
</def-item>
<def-item>
<term id="G8">DHLA</term>
<def>
<p>dihydrolipoic acid</p>
</def>
</def-item>
<def-item>
<term id="G9">EV06</term>
<def>
<p>lipoylcholine chloride</p>
</def>
</def-item>
<def-item>
<term id="G10">HDAC</term>
<def>
<p>histone deacetylase</p>
</def>
</def-item>
<def-item>
<term id="G11">Keap1</term>
<def>
<p>Nrf2-Kelch-like ECH-associated protein 1</p>
</def>
</def-item>
<def-item>
<term id="G12">KSS</term>
<def>
<p>Kearns-Sayre syndrome</p>
</def>
</def-item>
<def-item>
<term id="G13">MC</term>
<def>
<p>mitotic catastrophe</p>
</def>
</def-item>
<def-item>
<term id="G14">MNGIE</term>
<def>
<p>mitochondrial neurogastrointestinal encephalomyopathy</p>
</def>
</def-item>
<def-item>
<term id="G15">MSVI</term>
<def>
<p>moderate to severe vision impairment</p>
</def>
</def-item>
<def-item>
<term id="G16">Nrf2</term>
<def>
<p>nuclear factor erythroid 2-related factor 2</p>
</def>
</def-item>
<def-item>
<term id="G17">PD</term>
<def>
<p>Parkinson's disease</p>
</def>
</def-item>
<def-item>
<term id="G18">PEO</term>
<def>
<p>progressive external ophthalmoplegia</p>
</def>
</def-item>
<def-item>
<term id="G19">PK</term>
<def>
<p>pharmacokinetic</p>
</def>
</def-item>
<def-item>
<term id="G20">RNFL</term>
<def>
<p>retinal nerve fiber layer</p>
</def>
</def-item>
<def-item>
<term id="G21">RPE</term>
<def>
<p>retinal pigment epithelial</p>
</def>
</def-item>
</def-list>
</glossary>
</back>
</article>
</pmc-articleset>